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95% of the essential amino acid L-tryptophan (L-Trp) enters the kynurenine pathway (KP). The 
molecules produced in this pathway are known as the kynurenines and are associated with a number of 
diseases including Alzheimer’s disease, Huntington’s disease, cancer and acute pancreatitis. The 
enzyme kynurenine 3-monooxygenase (KMO) is part of the KP and catalyses the formation of 
3-hydroxy-L-kynurenine (3HK) from L-kynurenine (L-Kyn). Studies on animal models have shown the 
inhibition of KMO activity alleviates symptoms for a number of diseases associated with the KP. Due 
to difficulty in isolating human KMO much research has utilised KMO from the bacterium 
Pseudomonas fluorescens (PfKMO) as a model. Greater understanding of this protein could give rise 
to more effective treatments. 
This thesis describes the study of a modified PfKMO enzyme, called dm2. Dm2 is a more soluble 
protein than PfKMO and its behaviour is similar enough to make it an adequate model. The work is 
based upon x-ray crystallography, creating 3D models of dm2 and its variants. These 3D models allow 
us to view the interactions between dm2 and the molecule bound within it. The role(s) of different 
sections of dm2 can also be studied. This can include the building blocks of dm2, the amino acids, and 
the larger sections of the protein, the domains. 
Within this work amino acids within dm2’s active site, concerned with binding L-Kyn, were altered. 
The 3D models and catalytic efficiencies of these altered proteins were compared to dm2 and the 
importance of specific amino acids was confirmed. 
In previous work it was recognised that movement between two domains of dm2 gave rise to closed 
and open forms. It was hypothesised that the presence of L-Kyn caused dm2 to take on the closed form. 
This could have large implications in terms of the function of dm2. The 3D models with L-Kyn bound, 
however, came from crystals grown in a different form. This allowed for the possibility that the different 
crystal forms caused the movement of domains, rather than the presence of L-Kyn. 
The crystals grown in this work were all of the same form regardless of L-Kyn exposure and are 
therefore comparable. In L-Kyn-exposed and L-Kyn-free models two molecules are seen; one open, the 
other closed. This suggests that L-Kyn is not responsible for the movement of domains. However L-Kyn 
is only seen in the protein when in the closed form. The open molecule contains no L-Kyn. This 
therefore does not diminish the importance of the movement of the domains. 
In an attempt to study this movement amino acids were altered to inhibit dm2’s ability to take on the 
closed form. The results of this were inconclusive since the closed form was still present within the 
model. The levels of L-Kyn present were, however, severely affected, even in the closed form. This 
shows the role of the domain movement is not fully understood and requires further study. 
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Abstract 
The kynurenine pathway produces NAD+ from L-tryptophan. Metabolites known as the kynurenines 
are produced within the pathway. The effects of the kynurenines have been associated with a number 
of diseases including cancer, Alzheimer’s disease, Huntington’s disease, and acute pancreatitis. 
Kynurenine monooxygenase (KMO) is an enzyme that catalyses the conversion of L-kynurenine to 
3-hydroxy-L-kynurenine, the downstream product of which is the neurotoxic quinolinic acid. 
L-kynurenine is positioned at a branching point within the pathway. Metabolism via KMO leads to 
quinolinic acid production whereas conversion via kynurenine aminotransferase (KAT) produces the 
neuroprotective kynurenic acid. Inhibition of KMO leads to an increase in kynurenic acid concentration. 
This has also been shown to ameliorate the symptoms of neurological diseases in a number of animal 
models as well as to protect against multiple organ dysfunction caused by acute pancreatitis in rodent 
models. These findings present KMO as a promising drug target. 
Due to the hydrophobic nature of human KMO (hKMO) it has been necessary to utilise other forms of 
KMO as models. Past studies have produced crystal structures of a truncated Saccharomyces cerevisiae 
KMO and of Pseudomonas fluorescens KMO (PfKMO). Previous work in this research group has 
resulted in the structure of variants of PfKMO bound to either inhibitor molecules or substrate. These 
structures identified residues involved in substrate binding and the presence of a highly mobile section 
of the C-terminus, giving rise to open and closed conformations. It was surmised the movement of the 
C-terminus was dependent upon the presence of substrate and an interactive network between the 
C-terminus and the rest of the protein.  
Using improved crystallising conditions high-resolution structures of PfKMO have been produced that 
allow for further study of residues involved in substrate binding and the interactive network within the 
C-terminus. 
The mutants R84K and Y404F showed severely decreased enzyme activity. Crystal structures of these 
proteins showed disrupted interactions between substrate and active site. These findings underline the 
importance of residues R84 and Y404 in substrate binding. An H320F mutation gives an analogous 
active site to hKMO. Crystallographic and kinetic study of this mutant proved very similar to PfKMO, 
supporting the use of PfKMO as a model for hKMO. 
Throughout the work each structure had a P21221 space group with two molecules in the asymmetric 
unit. The presence of an open and closed molecule within each structure, including substrate-free 
molecules refuted the connection between C-terminus and substrate. R386K and E372T mutations were 
separately introduced in order to interrupt the interactive network. The presence of both open and closed 
conformations in the structures of R386K and E372T refutes the necessity for the interactive network 
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in C-terminus movement. The data analysed throughout the project suggest simple mobility and thermal 
motion as the cause of the movement of the C-terminus. 
This work, in conjunction with kinetic data from the thesis of Helen Bell, presents structural data to 
characterise the role of binding residues within the active site of KMO as well as the mechanistic role 
of the C-terminus. It also highlights the importance of certain binding residues and countered the 
previously held hypotheses surrounding the significance of the C-terminus. The mechanistic role of the 





Amino acid Three letter code One letter code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
 
Nucleotides: 












3-HA 3-hydroxyanthranilic acid 
3-HAO 3-hydroxyanthranilic acid oxygenase 
3-HK 3-hydroxy-L-kynurenine 
° Degrees 
°C Degrees Celsius 
Å Ångström 
AD Alzheimer’s disease 
AHR Aryl hydrocarbon receptor 
AMPAr α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
AP Acute pancreatitis 
ASU Asymmetric unit 
Cα Alpha carbon 
CC1/2 Correlation coefficient 
CNS Central nervous system 
cyt b5 cytochrome b5 
Da Daltons 
DC Dendritic cell 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTPs Deoxyribonucleotides 
DTT Dithiothreitol 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
FAD Flavin adenine dinucleotide 
FPLC Fast protein liquid chromatography 
g Gravity 
g (ng/μg/mg/kg) Grams (nano/micro/milli/kilo) 
GPR35 G protein-coupled receptor 35 
h Human 
HD Huntington’s disease 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IC50 Half maximal inhibitory concentration 
ix 
IDO1 Indoleamine 2,3-dioxygenase 1 
IDO2 Indoleamine 2,3-dioxygenase 2 
IFN-γ Interferon gamma 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
KA Kynurenic acid 
KAT Kynurenine aminotransferase 
kcat Turnover number 
Ki Dissociation constant of inhibitor 
KM Michaelis-Menten constant 
KMO Kynurenine 3-monooxygenase 
KP Kynurenine pathway 
L (nL/μL/mL) Litre (nano/micro/milli) 
LB Luria Bertani 
L-Kyn L-kynurenine 
L-Trp L-tryptophan 
M (nM/μM/mM) Molar (nano/micro/milli) 
m (nm/mm) Metre (nano/milli) 
MB Methylene blue 
MHPCO 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase 
min Minutes 
MW Molecular weight 
nAChR α7 nicotinic acetylcholine receptor 
NAD/NAD+ Nicotinamide adenine dinucleotide 
NADPH/NADP+ Nicotinamide adenine dinucleotide phosphate 
NCS Non-crystallography symmetry 
NFK N-formyl-kynurenine 
NMDAr N-methyl-D-aspartate receptor 
OD600 Optical density at 600 nm 
PAGE Polyacrylamide gel electrophoresis 
PCR Polymerase chain reaction 
PDB Protein data bank 
PEG x Poly-ethylene glycol, average molecular weight of x 
Pf Pseudomonas fluorescens 
PHBH Para-hydroxybenzoate hydroxylase 
PLP Pyridoxal 5’-phosphate 
PMSF Phenylmethanesulfonyl fluoride 
x 
p-OHB Para-hydroxybenzoate 
QA Quinolinic acid 
ROS Reactive oxygen species 
rpm Revolutions per minute 
s Seconds 
Sc Saccharomyces cerevisiae 
SDS Sodium dodecyl sulfate 
t1/2 Half-life 
TAE Tris-acetate-EDTA buffer 
TDO Tryptophan 2,3-dioxygenase 
Teff Effector T cell 
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Chapter 1: Introduction 
1.1. Overview of the kynurenine pathway 
The overall function of the kynurenine pathway (KP) in mammals is the conversion of the essential 
amino acid L-tryptophan (L-Trp) into the catabolic oxidising agent nicotinamide adenine dinucleotide 
(NAD+), as shown in Figure 1.1. This purpose was discovered in 1947 by Beadle et al. in a study on 
Neurospora1. The kynurenines themselves were discovered in 1904 by Ellinger who linked them to 
L-Trp in dog urine samples, hence their name2. In further studies it was found that 90 % of the L-Trp 
ingested enters the KP, while the other 10 % feeds into the serotonin and melatonin pathways and 
protein synthesis3, 4. Various equivalent proteins at the start of the KP are present in a number of bacteria 
including Pseudomonas aeruginosa, Pseudomonas fluorescens, and Streptomyces antibioticus5. These 
are associated with the production of quinolinic acid and anthranilic acid. Some bacterial species lack 
the aspartate to quinolinic acid pathway, including the order Flavobacteriales and genus Xanthomonas. 
These show genetic evidence for presence of the entire KP5. Several of the KP metabolites, such as L-
kynurenine (L-Kyn), kynurenic acid (KA), quinolinic acid (QA) and 3-hydroxy-L-kynurenine (3-HK) 
are involved in a number of pathologies including cancer, Alzheimer’s disease, acute pancreatitis, 
migraines and many more. The pathway involves numerous processes, enzymes and branching points; 




Figure 1.1 An overview of the kynurenine pathway (KP), steps with no named enzyme are non-enzymatic. 
Tryptophan 2,3-dioxygenase represented by TDO, indoleamine 2,3-dioxygenase represented by IDO, kynurenine 
aminotransferase represented by KAT. 
The KP starts with the oxidation of L-Trp to N-formyl-kynurenine (NFK) by one of three enzymes; 
these are tryptophan 2,3-dioxygenase (TDO), indoleamine 2,3-dioxygenase 1 (IDO1) and indoleamine 
2,3-dioxygenase 2 (IDO2). TDO is expressed predominantly in the liver, whereas IDO1 and IDO2 are 
expressed in various tissues6-8. NFK is rapidly hydrolysed to the more stable L-Kyn. 
L-Kyn sits at one of the branching points of the KP; its downstream products are associated with both 
neurotoxic and neuroprotective roles depending on which path is followed. If converted by kynurenine 
aminotransferase (KAT) the resulting KA is a known neuroprotectant9. If converted by kynurenine 3-
monooxygenase (KMO) the resulting 3HK is associated with neurodegeneration10. 3HK is further 
metabolised to form QA, which is also a known neurotoxin and this is eventually converted to the 
pathway’s main product NAD+. The later enzymes of the KP are found throughout the body in varying 
levels. The liver is the site of greatest expression for KMO and kynureninase but are found in many 
other tissues11, 12. KAT is expressed most in the brain and quinolinic acid phosphoribosyltransferase 
levels are highest in the kidney; both are expressed in various levels in other tissues13, 14.  
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1.2. Metabolites of the kynurenine pathway 
1.2.1. The L-tryptophan : L-kynurenine balance 
The immune response is a powerful mechanism that, if left unchecked, can lead to debilitating and even 
fatal conditions15. Amongst the many systems that suppress the immune system, in order to protect self-
cells, is the L-Trp : L-Kyn balance. 
The initial conversion of L-Trp to NFK is the slowest, and therefore rate-limiting, step of the whole 
pathway. Upon formation NFK is rapidly converted to L-Kyn and as the KP’s first stable metabolite a 
balance is formed between it and its precursor L-Trp. The ratio between the two plays a major role in 
immune response and is associated with a number of conditions relating to inflammation and 
immunology. This is modulated by L-Kyn production by the KP dioxygenases TDO, IDO1 and the 
recently discovered IDO2, and L-Kyn metabolism by KAT, KMO and kynureninase.  
The expression of the KP dioxygenases in inflamed tissues was originally explained as a way of starving 
pathogens of L-Trp16, 17. However this theory did not take into account the effect of L-Trp starvation 
upon the immune system itself. The perceived role of the dioxygenases altered drastically from the 
immune response to immunosuppressant when it was discovered that IDO1 expression prevented 
allogeneic foetal rejection within mice18. The presence of IDO1 was seen to cause T-cell inhibition and 
has since been linked to regulation of many other immune related cells, such as dendritic cells (DCs), 
monocytes, macrophages, and microglia19-21. This led to further study on the role of the L-Trp : L-Kyn 
balance within immune suppression. 
There are two theories as to how IDO1 produces such effects, one is L-Trp consumption and the other 
is the increase in kynurenine metabolites. Studies have suggested that both play a part in T-cell 
inhibition. 
The lack of L-Trp has been shown to abort mitosis of T-cells, induce autophagy and stop T-cell 
proliferation22, 23. The increase in kynurenine metabolites such as 3-hydroxyanthranilic acid and QA 
suppresses the response from T-cells and even leads to T cell apoptosis 24, 25. The alteration of the L-Kyn : 
L-Trp ratio also leads to naïve T-cells preferentially differentiating into regulatory T-cells, responsible 
for downregulating effector T-cells and reducing immune activity as a whole26. Evidence suggests this 
preferential differentiation is via aryl hydrocarbon receptor (AHR) activation27, 28. 
1.2.2. The kynurenic acid : quinolinic acid balance 
The later steps of the KP involve another ratio between the two neuroactive metabolites KA and QA. 
The concentrations of both these metabolites are reliant upon availability of precursor molecules. This 




1.2.2.1. Kynurenic acid 
KA is produced by the conversion of L-Kyn catalysed by the pyridoxal 5’-phosphate (PLP) dependant 
kynurenine amino transferase isozymes (KATs 1-4)29. Four KAT isozymes have been reported in 
mammals; each require an α-ketoacid coenzyme to act as the amino acid acceptor30. In 1982 KA was 
shown to be neuroactive and has been implicated in both therapeutic and pathogenic roles in various 
diseases31-33. KA binds to a number of different receptors throughout the nervous system and other areas 
of the body, many of which are associated with disease. These include the N-methyl-D-aspartate 
receptor (NMDAr), the kainite- and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
(AMPAr), the α7 nicotinic acetylcholine receptor (nAChR) as well as the G protein-coupled receptor 
35 (GPR35) and the aryl hydrocarbon receptor (AHR)34. 
The NMDAr is a subclass of glutamate receptor that regulates Ca2+ ion influx and it has long been 
associated with various neurological diseases. This can be through over-stimulation of the receptor 
causing neuron death, leading to neurodegenerative conditions such as Alzheimer’s disease, 
Huntington’s disease, and ischemic stroke. Subnormal activity of the receptor can also be detrimental 
and lead to schizophrenia and even neuronal apoptosis35, 36. Since KA is an antagonist it can act as a 
boon in some conditions and a bane in others. KA antagonism acts through competitive inhibition of 
the glycine co-agonist site of NMDAr with a Ki of 10 μM (IC50 = 36 μM)37. 
AMPAr is another subclass of glutamate receptor that requires a weaker stimulation than the NMDAr. 
When the AMPAr is stimulated this can trigger the stimulation of the NMDAr leading to Ca2+ influx38. 
At high (millimolar) concentrations KA acts as a competitive antagonist for AMPArs in a similar 
fashion to NMDArs. However, at low (submillimolar) concentrations KA has been shown to act as a 
“positive allosteric modulator”, facilitating AMPAr responses to glutamate39. This presents KA as an 
AMPAr agonist at physiological levels and antagonist at higher levels40. 
Nicotinic acetylcholine receptors (nAChR) also regulate the influx of cations but are triggered by 
acetylcholine and have been linked to cognitive functions such as memory and learning41. Through 
modulation of inflammation, the stimulation of nAChR has been associated with a number of 
neurological diseases, such as Alzheimer’s disease and schizophrenia42. KA is a non-competitive 
antagonist for nAChR with an IC50 much closer to physiological levels (submicromolar). This implies 
that the nAChR is the preferred target of endogenous KA43. 
KA has also been implicated in an immunological capacity. The AHR is a transcription factor involved 
in gene expression regulation leading to a number of responses associated with immunology and 
toxicology44. KA is a potent ligand for this receptor and elicits a response at physiological levels (IC50 
of 1.4 μM), and is therefore believed to be one of the few endogenous ligands of AHR45. The response 
to KA binding to AHR is the expression of interleukin-6, a mediator of inflammation and immune 
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response45. The AHR response to L-Kyn is also relevant in immune escape of cancer, which is further 
discussed in section 1.3.1. 
When at high concentrations KA also stimulates GPR35, a G protein-coupled receptor predominantly 
expressed in immune cells. This and the heightened levels of KA during inflammation gave rise to the 
theory that the two could play an important role in immunological modulation46, 47. However the 
discovery of GPR35 expression within the central and peripheral nervous systems has reduced the 
significance of KA’s possible role in this area48, 49. 
1.2.2.2. Quinolinic acid 
Quinolinic acid (QA) is the last precursor of the KP before NAD+ formation, and is mainly produced in 
the microglia50. The route to QA production within the KP starts at the branch point of L-Kyn, as shown 
in Figure 1.151. KMO converts L-Kyn to 3HK, which is cleaved by kynureninase to produce 
3-hydroxyanthranilic acid (3-HA). This is then converted to aminocarboxymuconate semialdehyde by 
3-hydroxyanthranilic acid oxygenase (3-HAO). This unstable intermediate cyclises non-enzymatically 
through condensation of the aldehyde with the amine to form QA52. 
QA was discovered to be neuroactive when it caused convulsions in mice after being injected into the 
brain53. It has since been established as a potent excitotoxin of the central nervous system (CNS) 
predominantly as an agonist for the NMDAr54. The uptake of QA within the synapse is relatively slow; 
this causes the activation of NMDAr to occur for an extended period of time, which in turn allows large 
levels of Ca2+ ions to enter the cell. This, as discussed above, leads to neuron death and is implicated in 
many neurodegenerative diseases55. QA neurotoxicity is most prevalently observed in the hippocampus 





Figure 1.2 Schematic of KA and QA within the nervous system and their effect on NMDAr and α7nAChR. Figure 
adapted from Maddison et al.58 
QA toxicity is also due to oxidative stress through various mechanisms in conjunction with, or 
independent of, the NMDAr. QA has been shown to increase nitric oxide synthase activity, producing 
free radicals and, through complexation with Fe2+, create reactive oxygen species (ROS), thus inducing 
lipid peroxidation59, 60. QA even acts as a double-edged sword, decreasing the ability of anti-oxidants 
such as glutathione and superoxide dismutase to deal with oxidative species61. 
1.2.3. 3-hydroxy-L-kynurenine 
3-hydroxy-L-kynurenine (3HK) is the direct oxidation product of KMO and is mostly found in the lens 
of the eye where it acts as a UV filter62. Studies suggest the levels of 3HK in the brain are low under 
normal conditions but are elevated under pathological conditions10, 63. 3HK has been assigned in the 
literature as both a beneficial antioxidant and a deleterious oxidative toxin. 3HK is capable of donating 
electrons and scavenging radicals, suggesting a role as an endogenous neuroprotectant64, 65. In more 
oxidative conditions, however, 3HK is capable of promoting ROS production in much the same manner 
as QA, leading to neuron death and oxidative stress66. Most of the evidence suggests that damage is 
caused when levels of 3HK are above normal physiological levels, advocating the case for 3HK as an 
endogenous antioxidant62. Under pathological conditions, however, the rise in 3HK concentrations may 
reach a tipping point towards harmful action. 
7 
 
1.3. The kynurenine pathway in disease 
1.3.1. Dioxygenases and cancer 
1.3.1.1. The L-Tryptophan : L-Kynurenine balance 
As mentioned in section 1.2.1 the L-Trp : L-Kyn ratio is inherently important in immune response 
modulation affecting T-cell growth, activity and differentiation. This is achieved through both 
decreasing L-Trp and increasing L-Kyn levels. While useful in preventing autoimmune reactions this 
system can also be beneficial to cancer cells. The expression of KP dioxygenases in order to perturb the 
L-Trp : L-Kyn balance can allow cancers to evade the immune system. 
Immune evasion is now seen as one of the “hallmarks” of cancer and different tumours exhibit a myriad 
of mechanisms in order to achieve it. Three common characteristics of immune modulation by cancers 
are evasion of immune recognition, chronic inflammation in the microenvironment and suppression of 
immune action67. The KP dioxygenases are predominantly involved in the latter. 
1.3.1.2. Expression of dioxygenases 
Constitutive expression of IDO1 in tumour cells was discovered in many human cancers in 2003; 
including prostatic, colorectal, pancreatic and cervical carcinomas68. The expression of TDO has also 
been identified in cancers such as bladder, colorectal, and hepatic carcinomas as well as glioblastomas69. 
The expression of IDO2 in some cancers has been reported. However, these have been disputed citing 
the presence as inactive IDO2 polymorphs; this is discussed further in section 1.4.3. The contradictions 
found within the literature add to the uncertainty of IDO2’s role70. 
1.3.1.3. Action of the aryl hydrocarbon receptor 
As the concentration of L-Kyn increases around cancer cells this leads to the activation of the AHR28. 
The AHR is a transcription factor that is regulated by planar aromatic hydrocarbons and L-Kyn activates 
AHR with an EC50 in the micromolar range (12-37 μM)71. When activated it translocates to the nucleus 
and binds to specific DNA strands thus activating certain genes. Under normal conditions activation of 
AHR has a wide range of results including cell development, cell migration and immune response. This 
can have a number of consequences relating to immunosuppression and immune escape of tumours. 
The positioning of the AHR dictates its action, as seen in Figure 1.3. The AHR can be on the cancer 




Figure 1.3 Schematic showing effect of L-Kyn activated AHR depending on the position of the AHR. Image 
adapted from Prendergast72. 
When AHR is activated on Teff cells their activity against cancer cells is reduced. In addition to this; 
levels of proliferation, activation and growth are also decreased71, 73. 
When AHRs located on naïve T-cells are activated by L-Kyn this leads to the generation of regulatory 
T-cells. These reduce the activity of Teff cells, lowering the immune response towards the cancer. This 
effect is increased when the AHR on DCs is activated. DCs are well known to play a role in naïve T-cell 
differentiation, and AHR activation causes the further expression of IDO1 and IDO2 by DCs. This in 
turn increases L-Kyn levels generating further Treg cells28, 74. If these DCs travel from the 
microenvironment surrounding the cancer to lymph nodes this can increase systemic tolerance, making 
metastasis more likely. 
When situated on the cancer itself AHR activation induces expression of genes that promote both cell 
growth and motility. This increases the likelihood of metastasis and malignancy71. 
The expression of KP dioxygenases, especially IDO1, has been shown to worsen a cancer patient’s 
prognosis significantly75. The knockdown of IDO1 in mice using both genetic and chemical based 
inhibition was shown to reduce cancer growth and increase effectiveness of anti-cancer drugs68, 76. IDO1 
is therefore an attractive drug target and several compounds are being investigated as potential IDO1 




A clinical trial of 1-methyl-D-tryptophan (1-DMT), shown in Figure 1.4, was started in 200778. The 
mechanism of action surrounding 1-DMT is disputed. 1-DMT exhibits no inhibition of IDO1 in vitro 
unlike its enantiomer 1-methyl-L-tryptophan (1-LMT)79. The literature is divided in the suitability of 
1-DMT as a potential drug. Its effects have been posited as the result of side reactions within the cell 
rather than direct action upon IDO180. Further uncertainty stems from the two different assays that have 
been used throughout the years, which are further discussed in section 1.4.3. 
More recent work by Tomek et al. evaluated the National Cancer Institute Diversity III library as IDO 
inhibitors81. The most promising compound, “pyrimidinone 4”, depicted in Figure 1.4, showed effective 
IDO1 inhibition (IC50 value 4.4 ± 1.5 μM) and low cytotoxicity (LC50 > 117 μM). 
 
Figure 1.4 a. Structure of 1-methyl-D-tryptophan (1-DMT). b. Structure of “pyrimidinone 4”. 
1.3.2. Kynurenine 3-monooxygenase and disease 
As mentioned in section 1.2.2 an alteration in precursor concentrations leads to a change in the balance 
between KA and QA. An increase in KA levels sees a drop in QA levels and vice versa. L-Kyn is seen 
as the branch point and has the potential to be converted to both of these metabolites. KMO catalyses 
the first step on the way to QA production. Inhibition of KMO causes a decrease in concentrations of 
both 3HK and QA; this in turn increases KA levels82, 83. Therefore inhibition of KMO is seen as a viable 
therapeutic strategy34, 84, 85. 
This section describes the role KMO plays in a number of diseases as well as the effect KMO inhibition 
has had upon models of these diseases. 
1.3.2.1. Huntington’s disease 
The neuroactivity of KP metabolites has led to the association of KMO with a number of neurological 
diseases84. Some of the most extensive work surrounding KMO is focused on its involvement in 
Huntington’s disease (HD). HD is a fatal genetic disease that causes neuron death due to the misfolding 
of the huntingtin protein86. The connection between HD and the KP was made through the similarities 
found in symptoms of rats with HD and those injected with QA87. Analysis of QA and KA 
concentrations soon corroborated this theory. KA levels are reduced in the cerebral cortex of HD mouse 
models and HD patients, while separate studies showed levels of QA to be elevated in HD mouse 
models and early-stage HD patients88-91. The impairment of mitochondrial function that is associated 
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with HD hinted towards KMO’s involvement and the first evidence of KMO’s clinical potential came 
in 200592. The deletion of the gene coding for KMO from yeast suppressed the toxic effects of a mutant 
huntingtin fragment in yeast while also eliminating QA93. Since then the knockdown of KMO has also 
shown reduction in QA levels and symptoms of HD in both mice and fruit fly models85, 94. 
1.3.2.2. Alzheimer’s disease 
Another neurological disease associated with the KP is Alzheimer’s disease (AD)95. AD causes plaques 
of misfolded peptides to form in the brain, as well as the phosphorylation of tau proteins96, 97. High 3HK 
and QA levels are present in AD patients and QA increases symptoms of AD such as tau 
phosphorylation and the expression of AD associated genes55. Chemical inhibition of KMO in mice saw 
an increase in concentrations of KA, which slowed the progression of the disease and ameliorated the 
symptoms presented84. In a more recent study the inhibition of both KMO and TDO led to reduction of 
symptoms of AD in fruit flies98. 
1.3.2.3. Stroke 
Due to its involvement in oxidative stress and neuronal damage the KP was investigated in its role in 
ischemic stroke. The levels of KP enzymes were found to be elevated in the hippocampus of 
post-ischemic mice, as was the level of QA in the brain overall99. Chemical inhibition of KMO reduced 
the amount of QA and 3HK in post-ischemic gerbil brains, and increased levels of KA. This reduced 
neuron death and decreased glutamate levels thus reducing oxidative damage100. 
1.3.2.4. Acute pancreatitis 
Recently KMO has been implicated in acute pancreatitis (AP) and the multiple organ failure that often 
follows101. The presence of 3HK is increased in mesenteric lymph tissue in rats, which increases 
cytotoxicity towards the lungs. The level of L-Kyn is also elevated in the blood of both rats and humans 
with AP101. In a collaborative study with GlaxoSmithKline, the use of KMO inhibitor GSK180 on AP 
model rats significantly altered the levels of KP metabolites in the blood stream. This provided effective 
protection against multiple organ failure11. 
The KP is associated with numerous other neurological conditions including Parkinson’s disease, 
amyotrophic lateral sclerosis, schizophrenia and even migraine34, 102-104. Many studies of these 
conditions have shown the modulation of the KP to produce a positive effect. KMO therefore presents 
itself as an attractive drug target for numerous conditions. 
1.4. Dioxygenases of the kynurenine pathway  
1.4.1. Tryptophan 2,3-dioxygenase 
TDO is a cytosolic homotetrameric b-type heme protein found most readily in the liver. It was first 
purified in 1936 and has high specificity towards L-Trp105. Its primary role is in regulation of the L-Trp : 
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L-Kyn ratio on a systemic scale. Crystal structures of Xanthomonas campestris TDO (XcTDO) and 
Ralstonia metallidurans TDO have revealed the enzyme to be more of a “dimer of dimers” given the 
N-terminal residues form part of the active site with the adjacent subunit, as shown in Figure 1.5106, 107. 
Since then Drosophila melanogaster TDO and human TDO structures have also been solved in 2013 
and 2014 respectively108, 109. The human enzyme structure, however, is of the apo protein and is without 
heme. 
  
Figure 1.5 Crystal structure of XcTDO in complex with heme and tryptophan. Left shows half of the tetramer, i.e., 
one dimer of dimers. Right shows L-Trp (orange) interacting with active site residues and heme (red). Residues 
from the N-terminus of the adjacent monomer are shown in green (PDB: 2NW8)106. 
1.4.2. Indoleamine 2,3-dioxygenase 1 
IDO1 is a monomeric b-type heme protein found throughout the body except the liver. Isolated in 1967 
IDO1 is more promiscuous than TDO, oxygenating various substrates in addition to L-Trp, including 
D-Trp, 1-Me-L-Trp, 5-F-Trp, serotonin and trytpamine110. IDO1 is expressed at lower levels than TDO, 
is present throughout the body, and its expression is strongly activated by interferon gamma (IFN-γ), a 
signalling molecule associated with immune response and inflammation. Also the KM for L-Trp of 
IDO1 (0.021 μM) is significantly lower than TDO (0.19 μM)111. It is believed therefore that IDO1 
regulation of the L-Trp : L-Kyn ratio is achieved within the local microenvironment in response to 
pathogenesis or injury112. Several crystal structures of the human IDO1 have been solved with inhibitors 
bound, showing two clear domains within the protein, as seen in Figure 1.6. The larger, all helical, 
domain is made of 13 α-helices and two 310 helices. This domain makes up most of the heme-binding 
pocket. The smaller C-terminal domain is formed of six α-helices, two β-sheets, and three 310 helices. 





Figure 1.6 Crystal structure of hIDO1 in complex with heme and 4-phenylimidazole (PI). A. Shows overall protein 
structure. B. Shows heme binding site with contributions from both small and large domains. Adapted from 
Sugimoto et al. (PDB: 2D0T)113. 
1.4.3. Indoleamine 2,3-dioxygenase 2 
IDO2 was discovered in 2007 and is much less well characterised than the other dioxygenases in the 
KP114. The gene for IDO2 is located very close to the IDO1 chromosome, making it a likely genetic 
predecessor of IDO1114. IDO1 and IDO2 share a BLAST sequence homology of 44%; an alignment of 




Figure 1.7 Sequence alignment comparing hIDO1 and hIDO2. Alignment generated using Clustal Omega116.  
The Uniprot identifier codes are hIDO1 - P14902, hIDO2 - Q6ZQW0. hIDO1 domains are represented through 
colours; the small domain is dark blue, the large domain is green, residues connecting the domains are red and 
light blue.  
IDO2 is expressed in some of the tissues that express IDO1, but unlike IDO1 is also found in the liver117. 
Activation of IDO2 expression by IFN-γ is less clear, with partial up-regulation occurring in human 
cells but not in other models such as mice118. IDO2 is inherently more hydrophobic and therefore less 
stable than IDO1 and this has led to difficulties isolating and analysing it. The enzyme, while able to 
catalyse the dioxygenation of L-Trp, is much less effective than IDO1 causing more difficulties in 
kinetic analysis. Activity of IDO1 and IDO2 has been examined using different assays, one based on 
methylene blue (MB), the other based on cytochrome b5 (cyt b5)119. A comparison of the kinetic 
properties of the two enzymes is shown in Table 1.1. 
  
                            1                  20                  40   
hIDO1      -----------------MAHAMENSWTISKEYHIDEEVGFALPNPQENLPDFYNDWMFIA 43 
hIDO2      MLHFHYYDTSNKIMEPHRPNVKTAVPLSLESYHISEEYGFLLPDSLKELPDHYRPWMEIA 60 
                              :.        :.***.** ** **:  ::***.*. ** ** 
 
                           60                  80                  100  
hIDO1      KHLPDLIESGQLRERVEKLNMLSIDHLTDHKSQRLARLVLGCITMAYVWGKGHGDVRKVL 103 
hIDO2      NKLPQLIDAHQLQAHVDKMPLLSCQFLKGHREQRLAHLVLSFLTMGYVWQEGEAQPAEVL 120 
           ::**:**:: **: :*:*: :** :.*..*:.****:***. :**.*** :*..:  :** 
 
                           120                 140                 160           
hIDO1      PRNIAVPYCQLSKKLELPPILVYADCVLANWKKKDPNKPLTYENMDVLFSFRDGDCSKGF 163 
hIDO2      PRNLALPFVEVSRNLGLPPILVHSDLVLTNWTKKDPDGFLEIGNLETIISFPGGESLHGF 180 
           ***:*:*: ::*::* ******::* **:**.****:  *   *::.::** .*:. :** 
 
                           180                 200                 220 
hIDO1      FLVSLLVEIAAASAIKVIPTVFKAMQMQERDTLLKALLEIASCLEKALQVFHQIHDHVNP 223 
hIDO2      ILVTALVEKEAVPGIKALVQATNAILQPNQEALLQALQRLRLSIQDITKTLGQMHDYVDP 240 
           :**: ***  *. .**.:  . :*:   ::::**:** .:  .::.  :.: *:**:*:* 
 
                           240                 260                 280           
hIDO1      KAFFSVLRIYLSGWKGNPQLSDGLVYEGFWEDPKEFAGGSAGQSSVFQCFDVLLGIQQTA 283 
hIDO2      DIFYAGIRIFLSGWKDNPAMPAGLMYEGVSQEPLKYSGGSAAQSTVLHAFDEFLGIRHSK 300 
           . *:: :**:*****.** :  **:***. ::* :::****.**:*::.** :***:::  
                                                                        
                           300                 320                 340 
hIDO1      GGGHAAQFLQDMRRYMPPAHRNFLCSLESNPSVREFVLSKGDAGLREAYDACVKALVSLR 343 
hIDO2      ES---GDFLYRMRDYMPPSHKAFIEDIHSAPSLRDYILSSGQDHLLTAYNQCVQALAELR 357 
            .   .:**  ** ****:*: *: .:.* **:*:::**.*:  *  **: **:**..** 
 
                           360                   380                 400  
hIDO1      SYHLQIVTKYILIPASQQ--PKENKTSEDPSKLEAKGTGGTDLMNFLKTVRSTTEKSLLK 401 
hIDO2      SYHITMVTKYLITAAAKAKHGKPNHLPGPPQALKDRGTGGTAVMSFLKSVRDKTLESILH 417 
           ***: :****::  *::    * *:    *. *: :***** :*.***:**..* :*:*: 
 
           Er 
hIDO1      EG- 403 







 mIDO1 mIDO2 
KM MB assay 28 ± 4 μM  12000 ± 3000 μM 
kcat MB assay 2.6 ± 0.1 s-1 0.02 ± 0.002 s-1 
KM cyt b5 assay 29 ± 9 μM 530 ± 100 μM 
kcat cyt b5 assay 0.09 ± 0.008 s-1 0.10 ± 0.008 s-1 
Table 1.1 A comparison of mouse IDO1 (mIDO1) and mouse IDO2 (mIDO2) Michaelis-Menten kinetic properties 
for the substrate L-Trp through two different assay systems119. 
The disparity in results for IDO2 between the MB and cyt b5 assays, suggests either an effective assay 
has yet to be found for IDO2 or that L-Trp is not the natural substrate for IDO2. This in turn would 
raise questions regarding the physiological function of IDO2. Another complication of IDO2 is the 
presence of its genetic polymorphs. These polymorphs either drastically reduce or totally cease IDO2 
activity and may be found in up to 50% of the population117. The high-resolution structure of IDO2 has 
yet to be solved leaving many questions about this refractory molecule unanswered. 
1.4.4. The dioxygenase mechanism 
The proposed chemical mechanism of the KP dioxygenases is believed to be conserved, but literature 
descriptions have been developed over the years as more evidence has come to light120. The initial step 
was proposed as a base-catalysed proton abstraction, as seen at position 1 in Figure 1.8121. This was 
supported by the fact that the inhibitor 1-methyl-tryptophan (1-MT), shown in Figure 1.4, was unable 
to undergo base abstraction since it lacked the necessary proton. The abstraction was then followed by 



























Figure 1.8 Initially proposed mechanism of KP dioxygenases. The heme plate is shown as a line surrounding Fe. 
The Criegee route is shown in blue, the dioxetane route is shown in red120. 
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However, when it was established that 1-MT is in fact a slow substrate, and the crystal structure of 
IDO1 showed the active site lacking any suitable base residue candidate, the base abstraction theory 
was abandoned122. The formation of a transient Compound II ferryl species, shown in Figure 1.9, was 
suggested through computational modelling and Raman data123-125. The presence of this ferryl species 
was confirmed by mass spectrometry when IDO1 turnover of several L-Trp analogues was studied. The 
presence of the appropriate ferryl species in all the L-Trp analogues indicates a common mechanism126. 
The formation of the ferryl species has been proposed via electrophilic addition and via radical addition; 
the steps following the formation of the ferryl species are based on QM/MM calculations; see Figure 









































Radical addition  
Figure 1.9 Current mechanism for TDO and IDO1. The heme plate is shown as a line surrounding Fe. The 
electrophilic addition route is shown on top, the radical addition route is shown on the bottom127, 128. 
1.5. Kynurenine 3-monooxygenase 
KMO is a type A flavoprotein aromatic hydroxylase that catalyses the conversion of L-Kyn to 3HK. 
The human form of KMO has a mass of approximately 55 kDa and is located in the outer membrane of 
the mitochondrion. It is predominantly expressed in the liver and kidney but is also expressed in 
microglia and infiltrating macrophages within the brain129, 130. 
The C-terminus of KMO binds to the outer mitochondrial membrane and is therefore very hydrophobic. 
This greatly reduces the stability of recombinantly expressed human KMO (hKMO) and therefore 
obtaining hKMO has been challenging, with early attempts only producing partial purifications of 
inactive enzyme131, 132. The C-terminus, due to its hydrophobicity, aggregates with other proteins and 
causes co-elution during purification attempts. Due to these problems, KMOs from other organisms 
have been used to study its mechanism and structure. KMO lends itself to these studies due to the high 
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level of conservation between KMOs of different species, especially in terms of the active site, as can 
be seen in Figure 1.10. 
 
Figure 1.10 Sequence alignment comparing KMO from various species. The active site residues are highlighted 
(yellow for conserved, red for non-conserved). Encircled PfKMO residues in bold are sites of mutation that are 
presented throughout this thesis. These include R84, Y404 and H320 in chapter 4 and R386 and E372 in chapter 
       1                   20       
P.fluorescens       ---------------------MTATDNARQVTIIGAGLAGTLVARLLARNGWQVNLFERR 39 
Homo_sapiens        --------------------MDSSVIQRKKVAVIGGGLVGSLQACFLAKRNFQIDVYEAR 40 
S.cerevisiae        --------------------------MSESVAIIGAGLVGCLAALAFSKEGYNVTLYDFR 34 
D.melanogaster      MSPGIVSQEVNGRQEPTEAARDERHGRRRRVAVIGAGLVGSLAALNFARMGNHVDLYEYR 60 
Sus_scrofa          --------------------MDSSDIQRTSIAVIGGGLVGSLNACFLAKRNFQVDVYESR 40 
                                                  :::**.**.* * *  ::: . :: ::: * 
 
   40                 60                       80               
P.fluorescens       PDPRIETGA--RGRSINLALAERGAHALRLAGLE--REVLAEAVMMRGRMVHVPGTPPNL 95 
Homo_sapiens        EDTRVATFT--RGRSINLALSHRGRQALKAVGLE--DQIVSQGIPMRARMIHSLSGKKSA 96 
S.cerevisiae        QDPRLDTTKNKNLKSINLAISARGIDALKSIDPDACEHILQDMIPMKGRMIHDLKGRQES 94 
D.melanogaster      EDIRQALVV--QGRSINLALSQRGRKALAAVGLE--QEVLATAIPMRGRMLHDVRGNSSV 116 
Sus_scrofa          EDIRMAEFA--RGRSINLALSYRGRQALKAIGLE--DQIVSQGIPMRARMIHSLSGKKSA 96 
                     * *       . :*****:: ** .**   . :   .::   : *:.**:*      .  
 
       100                 120          140             
P.fluorescens       QPYGRDDSEVIWSINRDRLNRILLDGAEA-AGASIHFNLGLDSVDFARQRL----TLSNV 150 
Homo_sapiens        IPYGT-KSQYILSVSRENLNKDLLTAAEKYPNVKMHFNHRLLKCNPEEGMI----TVLGS 151 
S.cerevisiae        QLYGL-HGEAINSINRSVLNNSLLDELEK-STTELKFGHKLVKIEWTDDKQICHFAIGED 152 
D.melanogaster      VLYDPINNQCLYSVGRRQLNEVLLNACDKLPNIRCHFEHKLTSANLREGSM----EFRNP 172 
Sus_scrofa          IPYGT-KSQYILSISRENLNKDLLTAVEKYPNAKVHFGHQLLKCRPETGVI----TLLGP 151 
                      *.  ..: : *:.*  **. **   :       :*   * .             .    
 
            160                 180                 200         
P.fluorescens       SGERLEKRFHLLIGADGCNSAVRQAMASVVDLGEHLETQPHGYKELQITPE------ASA 204 
Homo_sapiens        DKVPKDVTCDLIVGCDGAYSTVRSHLMKKPRFDYSQQYIPHGYMELTIPPK-------NG 204 
S.cerevisiae        LKTPHTEKYDFVIGCDGAYSATRSQMQRKVEMDFSQEYMNLRYIELYIPPTEEFKPNYGG 212 
D.melanogaster      AKEAVAAHADLIVGCDGAFSSVRQNNVRLPGFNYSQEYIETGYLELCIPSK-------SG 225 
Sus_scrofa          DKVPKDIACDLILGCDGAYSTVRTHLVKKPRFDYSQQYIPHGYMELTIPPQ-------NG 204 
                             .:::*.**. *:.*        :.   :     * ** *          .. 
 
                  220                 240                  260  
P.fluorescens       QFNLEPNALHIWPHGDYMCIALPNLDRSFTVTLFLHHQSPAAQPASPCFAQ-LVDGHAAR 263 
Homo_sapiens        DYAMEPNYLHIWPRNTFMMIALPNMNKSFTCTLFMPFE---------EFEK-LLTSNDVV 254 
S.cerevisiae        NFAIAPDHLHIWPRHKFMLIALANSDGSFTSTFFGSKD---------QISDLITSKSRVR 263 
D.melanogaster      DFQMPANYLHIWPRNTFMMIALPNQDKSFTVTLSMPFE---------IFAG-IQNQNDLL 275 
Sus_scrofa          DFAMEPNYLHIWPRDTFMMIALPNMNKSFTCTLFMPFE---------EFEK-LLTSRDVL 254 
                    :: :  : *****:  :* *** * : *** *:    :          :   :        
 
                     280                 300                    
P.fluorescens       RFFQRQFPDLSPMLD--SLEQDFEHHPTGKLATLRLTTWHV-GGQAVLLGDAAHPMVPFH 320 
Homo_sapiens        DFFQKYFPDAIPLIGEKLLVQDFFLLPAQPMISVKCSSFHF-KSHCVLLGDAAHAIVPFF 313 
S.cerevisiae        EFLIENFPDIINIMDLDDAVKRFITYPKESLVCVNCKPYDVPGGKAILLGDAAHAMVPFY 323 
D.melanogaster      EFFKLNFRDALPLIGEQQLIKDFFKTRPQFLVSIKCRPYHY-ADKALILGDAAHAMVPYY 334 
Sus_scrofa          DFFQKYFPDSLHLIGKEALAQDFFRLPAQPMISVKCSSFHF-NSHCVLMGDAAHALVPFF 313 
                     *:   * *   ::.     : *       :  :.   :.   .:.:::***** :**:. 
 
                      340                  360                  
P.fluorescens       GQGMNCALEDAVALAEHLQSA-ADNASALAAFTAQRQPDALAIQAMALENYVEMSSKVAS 379 
Homo_sapiens        GQGMNAGFEDCLVFDELMDKFSNDLSLCLPVFSRLRIPDDHAISDLSMYNYIEMRAHVNS 373 
S.cerevisiae        GQGMNCGFEDVRILMALLKKHSGDRSRAFTEYTQTRHKDLVSITELAKRNYKEMSHDVTS 383 
D.melanogaster      GQGMNAGMEDVTLLTDILAKQ-LPLDETLALFTESRWQDAFAICDLAMYNYVEMRDLTKR 393 
Sus_scrofa          GQGMNAGFEDCLVFDELMDKFNNDFSMCLPEFSKFRIPDDHAISDLSMYNYIEMRSHVNS 373 
                    *****..:**   :   : .        :  ::  *  *  :*  ::  ** **   .   
 
   380                 400                  420                 
P.fluorescens       PTYLLERELGQIMAQRQPTRFIPRYSMVTFS-RLPYAQAMARGQIQEQLLKFAVANHSDL 438 
Homo_sapiens        SWFIFQKNMERFLHAIMPSTFIPLYTMVTFS-RIRYHEAVQRWHWQKKVINKGL--FFLG 430 
S.cerevisiae        KRFLLRKKLDALFSIIMKDKWIPLYTMISFRSDISYSRALERAGKQTRILKFLESLTLGM 443 
D.melanogaster      WTFRLRKWLDTLLFRLF-PGWIPLYNSVSFS-SMPYRQCIANRKWQDQLLKRIFGATFLA 451 
Sus_scrofa          RWFIFQKNIERCLHTLMPSTFIPLYTMVTFS-RIRYHEAMLRWQWQKKVINTAL--FFFG 430 
                      : :.: :   :       :** *. ::*   : * ..: .   * ::::          
 
    440                 460 
P.fluorescens       TSINLDAVEHEVTRCLPPLSHLC---------------------------------- 461 
Homo_sapiens        SLIAISSTY-LLIHYMSPRSFLRLRRPWNWIAHFRNTTCFPAKAVDSLEQISNLISR 486 
S.cerevisiae        LSIGGYKLFKFLTRERS---------------------------------------- 460 
D.melanogaster      AIVTGGAIY--------AQRFL----------------------------------- 465 
Sus_scrofa          TLVALSTTY-LLTGPTFRSSLGCLRRSWNSVTYFQNIGRISL--------------- 471 
                      :                                                       
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5. C252 and C461 are discussed in chapter 1. PfKMO domains are represented through colours; blue is the 
FAD-binding domain, green is a domain conserved in flavoprotein monooxygenases, orange is a domain unique 
to KMO133. Alignment generated using Clustal Omega116. The Uniprot identifier codes are Saccharomyces 
cerevisiae – P38169, Pseudomonas fluorescens - Q84HF5, Drosophila melanogaster - A1Z746, Homo sapiens - 
O15229, Sus scrofa - Q9MZS9. 
1.5.1. Mammalian kynurenine 3-monooxygenase 
One of the first models for hKMO was pig KMO, which also suffered from co-elution with other 
unwanted proteins due to its hydrophobic C-terminus134. In attempting to solve this issue Hirai et al.135 
altered the KMO gene to truncate the C-terminus. The solubility of KMO increased but the activity was 
totally abolished. By altering truncation positions, that both increased and decreased activity, the last 
20 amino acids of KMO were identified as responsible for membrane localisation of the protein. The 
C-terminus was also recognised as playing a significant role in the activity of the enzyme. 
Later work has expressed human KMO recombinantly using human embryonic kidney (HEK) and 
Chinese hamster ovary (CHO-1) cells with no purification attempted136, 137. The expression of hKMO 
in E. coli was reported in 2014 and with the addition of a hydrophilic FLAG tag even resulted in active 
hKMO in the soluble fraction138. The resulting purification process, however, still resulted in co-elution 
with other proteins. When the C-terminus was truncated the activity of the protein was lost, matching 
the result of pig KMO. In another study a glutathione S-transferase-KMO fusion protein was expressed 
in COS-1 cells, and was successfully purified to a purification factor of 100139. 
1.5.2. Non-mammalian kynurenine 3-monooxygenase 
Research on non-mammalian KMO has been more successful. KMO from Saccharomyces cerevisiae 
(ScKMO) was successfully expressed recombinantly in E. coli and purified140. This was also a truncated 
form of the enzyme lacking the C-terminus. Unlike the pig or human KMO however, the activity of the 
enzyme remained unaffected. This led to the first structure of KMO being published, which is further 
discussed in section 1.6. 
Much work has been conducted on KMO from Pseudomonas fluorescens (PfKMO)11, 141-143. The main 
advantage of PfKMO is that being prokaryotic it is not membrane bound. The C-terminus, therefore, is 
much less hydrophobic and the protein is more stable overall. PfKMO has a 36% sequence identity to 
hKMO and the construct (kindly gifted by Graham Moran, University of Minnesota) is used throughout 
the work presented here. PfKMO was used to propose the mechanism of KMO and was recently used 
in a study on KMO inhibition as a treatment for multiple organ failure due to acute pancreatitis11, 142. 
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1.5.3. Para-hydroxybenzoate hydroxylase 
As previously mentioned KMO is a type A flavoprotein aromatic hydroxylase. This means the protein 
is encoded by one gene, contains one dinucleotide binding domain (Rossman fold), tightly and 
non-covalently binds an FAD cofactor, depends upon NADPH as a coenzyme, and NADP+ is 
immediately released upon FAD reduction144. The structure of FAD is shown in Figure 1.11. A number 
of well-studied type A flavoprotein aromatic hydroxylases have been used to direct the elucidation of 






















Figure 1.11 Structure of flavin adenine dinucleotide (FAD). 
PHBH is an enzyme that degrades aromatic compounds by adding an OH group, thus allowing further 
catabolism. It is an ideal model enzyme for the family of type A FAHs as it can be produced in high 
levels, is easily purified and is very stable145. The formation of FAD intermediate species throughout 
the reaction can also be easily followed using UV and fluorescence spectroscopy. This work produced 
a mechanism that became the model for flavoprotein monooxygenases. 
1.5.3.1. Mechanism of para-hydroxybenzoate hydroxylase 
The proposed mechanism is formed of two parts, a reductive half involving NADPH and an oxidative 
half involving O2145. The enzyme binds both NADPH and the substrate p-hydroxybenzoate (p-OHB) 
rapidly. This is followed by the rapid reduction of FAD, but this only occurs in the presence of the 
substrate p-OHB146. The release of NADP+ is relatively slow and is comparable to the overall reaction 
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rate. At this point in the reaction the undesirable release of p-OHB is very slow; this is to ensure that 
the reduced FAD does not react with O2 and produce toxic H2O2. The oxidative half of the reaction is 
very rapid, with O2 reacting to form flavin-C4a-hydroperoxide. This reacts with the substrate via 
electrophilic substitution to form the product 3,4-dihydroxybenzoate and flavin-C4a-hydroxide; this 
decays to FAD and water. The last step is release of product and water; water release is much slower 
than the product and is believed to be responsible for determining the overall reaction rate. A schematic 
of the main steps of the mechanism is seen in Figure 1.9. 
Figure 1.12 Schematic of the mechanism of PHBH. Stages show which conformation the protein is in, red is 
open, black is in and blue is out. Here and for the remainder of the thesis, the R group on the FAD isoalloxazine 
ring represents the rest of the dinucleotide. Mechanism proposed by Entsch et al.145, adapted from Cole et al.147. 
1.5.3.2. Structural conformations of para-hydroxybenzoate hydroxylase 
Throughout the stages of the reaction the protein cycles through a number of conformational states. 
First is the open conformation; this forms a path from bulk solvent to the interior of the protein, allowing 


















































































catalysis occurs. This conformation closes the path to the interior and excludes H2O from the active site 
ensuring no formation of H2O2 occurs. Further conformational changes within the active site are 
necessary for the reductive and oxidative half reactions. During the reductive half-reaction NADPH in 
the solvent requires access to the isoalloxazine of the FAD in order to reduce it, the protein is however 
in the closed conformation. This is overcome by the isoalloxazine moving 7-8 Å around the C-1’ to C-
2’ bond towards the surface of the enzyme, known as the out position. The movement is controlled by 
the presence of p-OHB increasing specificity towards p-OHB as a substrate. This movement is shown 
in Figure 1.14, depicting PHBH in complex with the product analogue 2,4-dihydroxybenzoate. The 




Figure 1.13 Structure of 2,4-dihydroxybenzoate 
 
Figure 1.14 Crystal structure of PHBH from Pseudomonas aeruginosa complexed with 2,4-dihydroxybenzoate 
(orange) at the active site. FAD is shown in both in (cyan) and out (magenta) conformations (PDB: 1DOE)149. 
A hydride is then transferred from NADPH and once reduced the isoalloxazine moves back to the in 
position. The flavin is now in a solvent free environment and reacts with O2 to form the 
flavin-C4a-hydroperoxide, which then reacts with the substrate. This movement of the isoalloxazine 
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allows the two half reactions to occur separately from each other, reducing the likelihood of H2O2 
formation. This movement gave rise to the term “waving flavin”. 
A number of other type A flavin monooxygenases have been characterised but to a lesser degree. Some 
of these exhibit a “waving flavin”, such as phenol hydroxylase; an enzyme isolated from Trichosporon 
cutaneum that catalyses the conversion of phenol to catechol150. The crystal structure exhibited a major 
conformational change associated with the in/out conformers. The largest residue movement between 
the two conformers was reported as exceeding 30 Å. Other type A flavin monooxygenases, like 2-
methyl-3-hydroxypyridine-5-carboxylic acid oxygenase (MHPCO), have not shown any evidence of a 
“waving flavin”. MHPCO catalyses the oxygenation of 2-methyl-3-hydroxypyridine-5-carboxylic acid 
in the vitamin B6 degradation pathway. Structural studies upon MHPCO have shown the protein only 
in one conformation similar to the in conformer151, 152. The presence of a solvent tunnel for substrate 
binding is also exhibited in these two examples.  
1.5.4. Mechanism of kynurenine 3-monooxygenase 
No evidence has been published that indicate KMO exhibits a “waving flavin”. Despite this, overall 
mechanism has been proposed to be similar to that of PHBH, albeit without the “waving flavin”. Using 
PfKMO Crozier-Reabe et al.142 investigated the reductive and oxidative half reactions of KMO using 
stopped-flow UV and fluorescence spectrophotometry. This has been used to elucidate the KMO 






















































































































































Figure 1.15 Schematic of the mechanism of PfKMO. The rates of most steps are included. The mechanism is 
split into 3 parts: ligand binding (blue), the reductive half-reaction (red) and the oxidative half-reaction (black)142. 
As with PHBH the rates of each step in the reaction have evolved to protect against formation of H2O2. 
For example, the rate of reduction of flavin by NADPH is stimulated 103-fold by the presence of 
L-Kyn142. Similarly to PHBH the last step, the release of product, is the slowest and is therefore 
rate-limiting142. However, evidence showed some differences to the PHBH mechanism. For example, 
the release of NADP+ is very rapid (104 s-1) while the oxygenation of substrate is relatively slow (5.9 
s-1). Study of KMO also shows evidence of a single complex of [KMO(red) · L-Kyn · NADP+] unlike 
PHBH which has two separate complexes as is required for the “waving flavin” movement, 
[Enzyme(ox) · Substrate · NADPH] and [Enzyme(red) · Substrate · NADP+]. 
1.5.4.1. P. fluorescens kynurenine 3-monooxygenase pharmacology 
In order to assess the viability of PfKMO as a surrogate for the human enzyme in a structure-based drug 
design approach, the pharmacology of both PfKMO and hKMO has been compared153. The pIC50 
values for 12 literature KMO inhibitors were assessed using LC/MS based analysis for PfKMO and 
hKMO. The pIC50 values showed a correlation when compared, with the inhibitors affecting PfKMO 
in a similar pattern to hKMO. The overall correlation had an R2 value of 0.83 and showed that all 
inhibitors had a greater effect on hKMO in general. The results can be seen in Figure 1.16153. This 




Figure 1.16 A graph to show the correlation of pIC50 values between PfKMO and hKMO. Drawn using data from 
source153. 
The KM of PfKMO and hKMO have also been shown by Hutchinson et al. as comparable, 7 μM and 
2 μM respectively, using a Rapidfire mass spectrometry assay133, 154.  
1.6. Structural studies of kynurenine 3-monooxygenase 
1.6.1. Saccharomyces cerevisiae kynurenine 3-monooxygenase structures 
The first published structures of KMO were of Saccharomyces cerevisiae KMO (ScKMO) truncated at 
residue 396 or 394140. The 396 truncation occurred through proteolysis within the cell, while the 394 
truncation was engineered. The engineered 394∆ enzyme showed turn-over of L-Kyn despite lacking 
the C-terminus, unlike the results obtained with pig KMO135. The 394 truncated enzyme was 
successfully crystallised both substrate-free and in complex with an inhibitor UPF 648, shown in Figure 
1.17, to resolutions of 1.82 Å and 2.13 Å, respectively. The enzyme in complex with UPF 648 is shown 




























Figure 1.18 Crystal structure of ScKMO bound with both FAD, shown in yellow, and inhibitor UPF 648, shown in 
orange (PDB: 4J36)140. The termini of the protein are shown here and throughout this thesis as C and N. 
The structure of ScKMO showed structural similarity to PHBH, reinforcing the position of PHBH as a 
model enzyme for type A flavoprotein aromatic hydroxylases. When overlaid using root mean square 
deviation (RMSD) of alpha carbons the alignment showed a RMSD value of 10.6 Å. As shown in Figure 
1.19, the FAD molecules take up similar positions within the proteins. See section 2.8.2 for further 




Figure 1.19 Overlay of the crystal structures of ScKMO in cyan (PDB: 4J36) and ScPHBH in green (PDB: 1PHH) 
both bound with FAD, shown in yellow140, 155. RMSD = 10.6 Å from 291 aligned Cα atoms. 
Some of the key binding residues interacting with the UPF 648 carboxylate were R83 and Y97; these 
are conserved throughout the KMOs, see Figure 1.10140. The aromatic part of the inhibitor was 
surrounded by hydrophobic residues, many of which are also conserved. The importance of residue R83 
was demonstrated through mutagenesis140. When substituted by alanine or methionine the enzyme 
exhibited 25% and <3% of wild-type activity, respectively. The substitutions also led to a 20-fold drop 




Figure 1.20 Crystal structure of the active site of ScKMO showing interactions between UPF 648 and residues 
R83 and Y97 (PDB: 4J36)140. Distances between atoms are in Å and shown as red dashed lines. 
A change in structure is seen when ScKMO binds UPF 648; the loop P321-Q325 re-orientates increasing 
the disorder of the C-terminus α-helix. This movement is caused by F322 moving away from the active 
site to accommodate the two chloride groups in UPF 648 that have no equivalent groups in L-Kyn. 
These conformational changes can be seen in Figure 1.21. 
 
Figure 1.21 Crystal structure showing the movement exhibited by ScKMO upon UPF 648 binding. The UPF 648 
bound model is shown in green, the unbound model shown in blue. RMSD = 0.793 Å from 349 aligned Cα atoms. 
Left shows residues F322 and Y323, right shows the loop P321-Q325 (PDB: 4J36, 4J33)140. 
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Despite advances in understanding of active site interactions some potentially important residues were 
impossible to investigate due to the C-terminus truncation of ScKMO. The truncation also precluded 
the investigation of any conformational change within the C-terminus upon ligand binding. 
1.6.2. Pseudomonas fluorescens kynurenine 3-monooxygenase structures 
In early 2016 a structure of PfKMO in complex with inhibitor GSK180 was published to a resolution 
of 3.19 Å, see Figure 1.22. The importance of residue R84, the equivalent of ScKMO’s R83, was 
demonstrated by the existence of an apparent salt bridge between it and the carboxylate group of the 
inhibitor. The residues Y98 and N369 also form H-bonds with the carboxylate, while Y404 is shown 
interacting with the carbonyl. 
 
Figure 1.22 Left shows the crystal structure of the active site of PfKMO interacting with the inhibitor GSK180, the 
structure of which is shown on the right. Image adapted from Mole et al. (PDB: 5FN0) 11. 
Structural study of PfKMO has been on going within the Mowat group for several years. Crystals were 
originally grown in conditions using HEPES and polyethylene glycol 4000 (PEG 4K) but did not 
diffract well. The protein itself was inherently unstable and lost activity over time in the absence of a 
reductant. It was hypothesised that this was due to disulfide bonds forming between molecules141. Two 
cysteine to serine mutations were introduced at the C-terminal residues to give C252S/C461S, a double 
mutant referred to in this work as dm2143. This greatly improved the stability of the protein, as shown 
in Table 1.2. The kinetic analysis showed there was no significant difference in turnover or substrate 





Protein KM (μM) kcat (s-1) t1/2 (hours) 
Wild type 14.5 ± 2.5 9.1 ± 1.6 7.9 ± 2.6 
C252S 18.7 ± 5.9 6.8 ± 0.6 53.5 ± 24.3 
C461S 15.5 ± 4.2 6.4 ± 0.5 31.5 ± 2.3 
dm2 8.8 ± 1.5 8.9 ± 1.1 75.2 ± 5.2 
Table 1.2 Michaelis-Menten kinetics and enzyme half-life for PfKMO and cysteine to serine mutants. t1/2 
calculated from time required for half enzyme activity to be lost when incubated at 25 °C143. 
Crystals of dm2 diffracted to a greater degree and using selenomethionine substitution and 
multi-wavelength anomalous dispersion a structure of substrate bound dm2 was solved. The space 
group was I4122 with a solvent content of over 80% leading to a relatively low resolution of 3.4 Å. This 
led to the first crystal structure of KMO with an intact C-terminus and the first in complex with L-Kyn, 
this is shown in Figure 1.23. 
 
Figure 1.23 Crystal structure of dm2 bound with L-Kyn (orange)143. The C-terminal domain is shaded light green. 
Despite the low resolution the presence of substrate was confirmed and the positioning of the substrate 
molecule could still be determined, as seen in Figure 1.24. Interactions with key binding residues could 
also be identified and these can be seen in Figure 1.25. The residues identified matched with equivalents 
in the previously mentioned ScKMO work, including R84 and Y98. Other residues, including those 
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impossible to characterise in the truncated ScKMO, were recognised as having substrate interactions, 
such as N369, Y404 and H320. 
 
Figure 1.24 Crystal structure of dm2 bound with L-Kyn143. The 2Fo-Fc map is shown in blue (contoured at 
0.12 eÅ-3, 1.50 σ) and the Fo-Fc map, calculated in absence of L-Kyn, is shown in green (contoured at 




Figure 1.25 a. Crystal structure of the active site of dm2 bound with L-Kyn (orange). b. Chemdraw schematic of 
dm2 bound with L-Kyn. Distances between atoms are in Å and shown as red dashed lines. The site of oxidation 
is denoted with an asterisk (*). 
1.6.3. C-terminus movement 
The structure of ligand-free dm2 was also solved to a resolution of 2.26 Å143. Crystals belonged to space 
group P21221 and showed a solvent content of roughly 50%. The majority of the protein showed high 
similarity with the substrate-bound model. There was, however, a significant movement observed 
within the C-terminus between the bound and unbound structures. Compared to the substrate-free form, 
the substrate-bound form showed a movement of up to 6.1 Å at residue 381 and implied the existence 
of open and closed conformations. As seen in Figure 1.26, the surface of the protein shows a clear 
channel to the active site in the open position, which then disappears when in the closed position. This 
appears similar to the conformational change seen in PHBH, as discussed in section 1.5.3.2, which 





Figure 1.26 Surfaces of crystal structures of dm2. The substrate bound closed position is shown on the left, the 
substrate free open position, with channel leading to isoalloxazine of FAD, is shown on the right. The C-terminus 
is shown in a lighter shade. An enlarged view of the ligands is also shown. 
The positioning of residues between the mobile C-terminus and the main body of the protein were 
investigated and a putative network of interactions was identified. In the substrate-bound model many 
of the residues are within electrostatic or H-bonding distance of each other and also of L-Kyn, with R84 
playing a key role between the two. In the substrate-free model the residues are well out of range for 





Figure 1.27 Crystal structures of dm2, showing distances between residues in the putative bonding network of 
the C-terminus143. Left shows the closed position, right shows the open position. Distances between atoms are in 
Å and shown as red dashed lines. 
This proposed network was investigated further by site-directed mutagenesis of the key residues 
involved, and analysis of the crystallography and kinetics of these mutant forms of PfKMO. 
A comparison of C-terminus swing was made based on the movement of the Cα atom of T381, 
comparing the original substrate-bound dm2 structure to the structure in question143. This is shown in 
Table 1.3. A decrease in C-terminus movement was seen in all mutants, placing the substrate-bound C-
terminus in an intermediate position between open and closed conformations, known as a mixed position. 
Protein KM (μM) kcat (s-1) C-terminus swing (Å) 
bound/unbound 
dm2 8.8 ± 1.5 8.9 ± 1.1 0.0/6.1 
E372T dm2* 10.3 ± 0.7 8.7 ± 0.1 3.7/n.a. 
R386K dm2 17.0 ± 1.4 12.0 ± 0.9 4.2/6.1 
R386T dm2 63.9 ± 2.4 15.2 ± 1.3 4.3/6.1 
Y382F dm2 17.1 ± 1.0 12.7 ± 0.2 3.8/n.a. 
Table 1.3 Summary of Michaelis-Menten kinetic data and extent of C-terminus swing for mutant forms of dm2143. 
(n.a. is shown where no data exist). *E372T mutant also contained a L367R mutation. 
The space groups of each substrate-bound mutant structure were also I4122 leading to a high solvent 
content and low resolution, the highest being 3.24 Å. The fact that each mutant showed the same space 
group, even with a more open conformation, implied that the C-terminus movement was dependent on 
the protein and not the crystal packing. This does not, however, totally remove the possibility that the 
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presence of L-Kyn is responsible for the change in space group. The different space groups could in 
turn form different crystal contacts that could be the cause of the C-terminus movement. 
A third space group, P6122, was observed in crystals of dm2 bound to a number of tightly binding 
inhibitors based upon the known KMO inhibitor Ro 61-804884. These inhibitors showed Ki values 
between 0.02 and 2.77 μM. They bound to dm2 much like L-Kyn, but all the molecules within the ASU 
took up a conformation similar to the open unbound form. This was rationalised as the tails of the 
inhibitors disrupting the interactive network of the C-terminus143.  
Overall the hypothesis of C-terminus dynamism being linked to mechanism still requires further 
confirmation before firm conclusions can be drawn. 
The resolution of PfKMO structures allowed for identification of potentially important residues. They 
showed possible interactions in the active site and C-terminus but did not allow for detailed analysis of 
these interactions. Due to co-ordinate error, in a 3.4 Å resolution structure with high overall B-factors, 
a distance measured as 3.2 Å associated with a weak H-bond may in-fact be a close strong interaction 
or a very weak distant interaction. 
1.6.4. Kinetic analysis of dm2 mutants 
The residues highlighted within the active site, including R84, Y404, H320, and N369 were assessed 
for their importance in enzyme activity by site-directed mutagenesis. The conservative mutations were 
Y404F, R84K, N369S and H320F. The mutants were then characterised via Michaelis-Menten kinetic 
analysis. All mutants and kinetic data were produced by Helen Bell156. 
Enzyme KM (μM) kcat (s-1) kcat/KM (s-1 μM-1) 
dm2 8.8 ± 1.5 8.9 ± 1.1 1.01 
Y404F 96.5 ± 4.0 6.2 ± 0.1 0.06 
R84K 0.0 0.0 0.0 
N369S 27.7 ± 3.3 4.5 ± 0.2 0.16 
H320F 18.0 ± 1.2 7.1 ± 0.2 0.39 
Table 1.4 Summary of Michaelis-Menten kinetic data for mutant forms of dm2. R84K showed no measurable 
activity and is reported as zero156. 
The variants that showed the greatest change in turnover and binding were Y404F and R84K. The 
efficiency of Y404F is decreased by a factor of ~10 and the R84K enzyme showed no turnover 
whatsoever, totally inactivating the enzyme. These residues were hence identified as the most 
interesting in terms of their influence on function. 
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Crystal structures of these mutants were solved but suffered once again from low resolution and high 
solvent content, especially when substrate was bound. This made it difficult to assign a position to 
L-Kyn within the active site.  
1.7. Aim 
Throughout this chapter it can be seen that KMO is a viable drug-target for a number of diseases 
including Huntington’s disease, Alzheimer’s disease, brain ischemia and acute pancreatitis. PfKMO 
dm2 has been used as a model for hKMO and has been involved in the development of a lead molecule. 
In an effort to validate previous structural models, further characterisation of key binding residues is 
therefore necessary.  Better understanding of the mechanism of KMO is also required, particularly 
concerning the role of the C-terminus and the static nature of the FAD. 
Despite the information previously gleaned from both kinetic and crystallographic work the theories 
surrounding PfKMO require further clarification. The previous crystal structures of PfKMO highlighted 
potentially important residues within the active site and a putative C-terminus bonding network. 
However due to low resolution data the exact positions and roles of these residues are yet to be 
pinpointed. The kinetic data collected on PfKMO mutants has verified the importance of certain 
residues within the active site, but the reasoning behind these changes in kinetic data is yet to be fully 
established. 
The aim of this work is to rationalise the importance and function of these highlighted residues in the 
active site and to clarify the presence of a C-terminus H-bonding network within dm2 through 




Chapter 2:  Materials and Methods 
2.1. Materials 
All water was purified using a Sartorius arium 61316 water purifier. All chemicals used were ≥97 % 
pure. All chemicals were purchased from Sigma Aldrich unless otherwise stated. 
2.2. DNA cloning 
2.2.1. Primer sequence design 
Primers used in Sanger sequencing are listed in Table 2.1. Each was purchased in dry form, dissolved 
in water to a concentration of 100 μM and stored at -20 °C. 
 
Table 2.1 Primer sequences used in Sanger sequencing. 
2.2.2. pET plasmid transformation 
pET plasmids containing the gene of interest were used to transform BL21 (DE3) E. cloni® EXPRESS 
chemically competent cells sourced from Lucigen®. Cells were removed from -80 °C storage and 
thawed on ice, and 40 μL of cells was transferred to a pre-chilled sterile culture tube (15 mL). 1 μL 
DNA was added and briefly stirred with a pipette tip. The cells were incubated on ice for 30 mins, heat 
shocked in a 42 °C water bath for 45 seconds and returned to ice for 2 minutes. 960 μL Lucigen® 
Expression Recovery Medium was added to the tube and incubated for 1 hour at 37 °C with shaking at 
250 rpm. 100 μL of cells was plated onto LB agar plates (see section 2.3.1) containing 50 μL/g 
ampicillin and incubated overnight at 37 °C. 
2.2.3. Plasmid extraction 
10 mL LB with 50 μg/L of the relevant antibiotic was inoculated with cells in 30 mL sterile tubes and 
incubated at 37 °C with shaking at 200 rpm for 16 hours. The cells were harvested by centrifugation for 
10 minutes at 8000 rpm at 4 °C in 60 mL flasks using a Sorvall RC 6 Plus centrifuge and a Sorvall SS-
34 rotor. The plasmid was extracted from the cell pellet using a QIAprep Spin Miniprep Kit and eluted 
with 40 μL elution buffer into a sterile Eppendorf tube. 
Primer Sequence 
T7 promoter TAATACGACTCACTATAGGG 
T7 terminator GCTAGTTATTGCTCAGCGG 
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2.2.4. Cell stock preparation 
900 μL of sterile LB media (see section 2.3.1) with no antibiotic was placed in a sterile Eppendorf tube. 
Cells were introduced to the media; the tube inverted several times and incubated at room temperature 
for 10 minutes. 100 μL of dimethyl sulfoxide (DMSO) was added and the tube stored at -80 °C for long-
term storage. 
2.2.5. Sanger sequencing 
Sanger sequencing was performed by the University of Edinburgh based company The Genepool using 
BigDye v3.1 Terminator Cycle Sequencing Kit from Thermofisher. Each sample was prepared in a 0.2 
mL strip tube with 5 μL plasmid DNA and 1 μL sequencing primer (3.2 μM). Each plasmid was 
sequenced in both forward and reverse using primers for T7 promoter or T7 terminator respectively. 
The results were combined to show the full gene sequence. 
2.3. Cell growth and Harvest 
All protein-producing bacteria were recombinant BL21 E. coli containing the λDE3 lysogen that carries 
the T7 RNA polymerase gene. 
2.3.1. Media 
All bacteria were grown in Luria Bertani media. To prepare Luria Bertani (LB) media the following 
were dissolved in water: 
10 g/L tryptone (Sigma Aldrich) 
5 g/L yeast extract (Scientific Laboratory Supplies) 
5 g/L NaCl 
All media were adjusted to pH 7.0 with NaOH and autoclaved at 121 °C for 20 minutes. 
All subsequent supplements to the media, such as ampicillin, were sterile filtered through 0.45 μm 
Millipore filters. 
LB agar plates were prepared by adding 15 g/L agar to LB media before autoclaving. The solution was 
cooled to 40 °C before antibiotic was added, the media poured into sterile Petri dishes and allowed to 
cool. 
To prepare X-Gal/IPTG plates 10 μL X-Gal solution (20 mg/mL) and 10 μL isopropyl 




2.3.2. PfKMO growth 
All PfKMO proteins were produced using a pET17b expression vector containing the appropriate KMO 
gene. 10 mL aliquots of LB with 50 μg/L ampicillin were inoculated with cells in 30 mL sterile tubes 
and incubated for 24 hours at 37 °C with shaking at 180 rpm. These 10 mL growths were then added 
to separate 1 L baffled flasks containing 1 L LB media supplemented with 50 μg/L ampicillin and 
incubated at 22 °C with shaking at 180 rpm for 16 hours. 
2.3.3. Cell Harvest 
Cells were harvested by centrifugation for 10 minutes at 2704 x g at 4 °C in 500 ml flasks using a 
Sorvall RC 6 Plus centrifuge and a Sorvall SLA-3000 rotor. The cell pellets were stored at -20 °C until 
required. 
2.4. Protein purification 
2.4.1. PfKMO purification 
The buffers used in PfKMO purification are listed in Table 2.2. All buffers were pH adjusted using 
NaOH or HCl and filtered through a 0.45 μm filter. 
Lysis buffer 20 mM HEPES pH 7.5 
10 mM NaCl 
1 mM DTT 
Wash buffer 20 mM HEPES pH 7.5 
50 mM NaCl 
1 mM DTT 
Elution buffer 20 mM HEPES pH 7.5 
110 mM NaCl 
1 mM DTT 
Ammonium sulfate solution 20 mM HEPES pH 7.5 
75 % saturated ammonium sulfate 
1 mM DTT 
Size exclusion buffer 20 mM HEPES pH 6.8 
10 mM NaCl 
1 mM DTT 
Table 2.2 Compositions of PfKMO purification buffers. 
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Cell pellets were thawed on ice and resuspended in 10 mL lysis buffer per gram of cell mass. The 
suspension was supplemented with phenylmethanesulfonyl fluoride (PMSF) to a concentration of 
0.2 mM. The solution was ultrasonicated on ice in 20-second bursts for a total of 2 minutes with cooling 
between bursts. This suspension was then centrifuged for 1 hour at 47808 x g at 4 °C in 60 mL tubes 
using a Sorvall RC 6 Plus centrifuge and a Sorvall SS-34 rotor. 
The supernatant was filtered through 0.45 μm syringe filters and loaded onto a 60 mL FPLC 
Q Sepharose 26/10 column pre-equilibrated with lysis buffer. 400 mL wash buffer was then used to 
wash the column. The protein was then eluted using 500 mL elution buffer. The protein was collected 
by an automated fraction collector. The fractions were tested for PfKMO content using an absorbance 
of at 450 nm and for activity using a kinetic assay described in section 2.6.1. 
In order to precipitate the protein, pooled fractions of PfKMO were mixed slowly on ice with 75% 
saturated ammonium sulfate solution to reach a final saturated concentration of 50%. After 30 minutes 
incubation on ice the suspension was centrifuged for 20 minutes at 47808 x g at 4 °C in 60 mL tubes 
using a Sorvall RC 6 Plus centrifuge and a Sorvall SS-34 rotor. The pellets could be stored at -20 °C 
prior to further purification. 
The pellets were resuspended on ice using minimal amounts of size exclusion buffer.  The solution was 
concentrated by centrifugation using VIVASPIN MW 30000 concentrators to a volume of 2 mL. This 
was loaded onto a 320 mL 26/600 Superdex 75 column pre-equilibrated with size exclusion buffer. The 
protein was collected by an automated fraction collector monitored by UV absorbance at 280 nm. 
The fractions were tested for purity and concentration using absorbance measurements described in 
section 2.5.2 and pooled. The concentration of protein was adjusted as necessary for future use and the 
protein was aliquoted and flash frozen in liquid nitrogen before being stored at -80 °C. The yield of 
each preparation varied between 1-2 mg of pure protein per litre of LB media in the initial growth. 
2.5. Protein purity analysis 
2.5.1. SDS-PAGE analysis 
Liquid samples were mixed in a 1:2 ratio with novex® NuPAGE® LDS sample buffer (4×), small 
scrapings of solid samples were mixed with 20-40 μL of the same buffer to prevent overloading. 
Samples were boiled for 5 minutes and loaded onto a pre-cast novex® NuPAGE® 4-12% Bis-Tris gel 
in novex® NuPAGE® MES SDS running buffer. 4 μL novex® SeeBlue® Pre-Stained Standard was 
added as a protein marker. Gels were run at 150 V for 1 hour. Gels were stained for 1 hour with gentle 
shaking using a solution comprising 0.1% Coomassie Brilliant Blue G-250, 40 % methanol, 10 % acetic 
acid and 50% water. The gel was washed and de-stained with water overnight. 
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2.5.2. UV-Vis spectrophotometry 
All UV-Vis spectrophotometry was performed using a Cary UV-Vis 50 Probe spectrophotometer with 
a quartz cuvette of path length 1 cm. To assess concentration and purity of protein solutions a scan 
between 600-240 nm was performed using the relevant buffer as a blank. 
The concentration was calculated using the Beer-Lambert law using the molar absorbance for flavin at 
450 nm (12300 M-1 cm-1). Using prior experience purity was analysed by comparing the aromatic 
residues absorbance at 280 nm to the flavin absorbance at 450 nm with a respective ratio of 7:1 
considered pure.  
2.5.3. Mass Spectrometry 
Any liquid chromatography electrospray ionisation mass spectrometry was performed using 15 μL of 
~15 μM protein. This was loaded onto an Aeris Widepore 3.6 μm C4 50 x 2.1 mm column connected 
to a Waters ZSpray Lockspray electrospray ionisation source. This was then analysed using a Synapt™ 
G2 time of flight mass spectrometer. The peaks analysed were those that gave a protein envelope 
spectrum. The program used to visualise and calculate the mass of the peak was Masslynx (Waters, 
Version V4.0). 
2.6. Protein Kinetic Analysis 
2.6.1. PfKMO Kinetic assay 
Kinetic activity was monitored using a Cary UV-Vis 50 Probe spectrophotometer monitoring at 340 nm 
over 30 seconds with a quartz cuvette of path length 1 cm. This absorbance corresponds to the peak for 
NADPH, and this falls as it is consumed (to form NADP+) as it reduces PfKMO. All data were collected 
at 25 °C controlled by a thermostatic water bath. The assay buffer components and final concentrations 
are shown in Table 2.3. 
Assay component Final Concentration 
HEPES buffer, pH 8.0 20 mM 
NADPH 220 μM 
L-kynurenine Various 
PfKMO 0.1-0.5 μM 
Table 2.3 Composition of PfKMO kinetic assay. 






∆ 𝐴𝐴𝐴𝐴𝐴𝐴𝑇𝑇𝑇𝑇𝐴𝐴𝐴𝐴𝑇𝑇𝐴𝐴𝑇𝑇 (340 𝑇𝑇𝑛𝑛)
60 ×  𝜀𝜀 (𝑁𝑁𝐴𝐴𝑁𝑁𝑁𝑁𝑁𝑁 𝐴𝐴𝑎𝑎 340 𝑇𝑇𝑛𝑛) ×  [𝑇𝑇𝑇𝑇𝑒𝑒𝑒𝑒𝑛𝑛𝑇𝑇]
 
Equation 2.1 Calculation of enzyme turnover (s-1) where Δ Absorbance is the change in absorbance at 340 nm 
(min-1), ε is the extinction coefficient of NADPH at 340 nm (6200 M-1 cm-1)157 and [enzyme] is the concentration of 
enzyme (M). 
2.6.2. Data modelling 
In order to determine KM and kcat kinetic data were fitted using the Michaelis-Menten function in Origin 
2015 (OriginLab, Northampton, MA).  
2.7. Crystallography 
2.7.1. Hanging-drop vapour diffusion 
Linbro 24-well plates were used to grow crystals. Each well was filled with 0.5 mL well solution. Well 
solutions varied in concentration of polyethylene glycol 8000 (PEG 8K) and pH to increase likelihood 
of crystal growth. The components and concentrations of well solution are shown in Table 2.4. 
Well solution component Final Concentration 
PEG 8K 11-21% 
Sodium cacodylate pH 5.5-7.0 0.08 M 
Calcium acetate 0.16 M 
Glycerol 20% 
Table 2.4 Composition of crystal well solution. 
1 μL of purified ~250 μM PfKMO was placed on a siliconized glass cover slip and mixed with 1 μL of 
well solution. The slide was sealed onto the well using paraffin grease and the well plate wrapped in 
aluminium foil to block out light and stored at 18 °C in a vibration free room. 
2.7.2. Streak seeding 
To encourage crystal growth streak seeding was sometimes employed. A crystal of the relevant protein 
was crushed in the hanging drop using a glass crystal crusher. 5 μL of well solution supplemented with 
PEG 8K to a concentration of 25 % was added to the drop. This was then placed in an Eppendorf tube 
on ice, to which 45 μL well solution was added and the tube vortexed for 1 minute. Serial dilutions of 
the seeding solution were made using mother liquor supplemented with PEG 8K to a concentration of 




To seed the hanging drop a seeding tool (synthetic hair) was dipped into a seeding solution and dragged 
horizontally through the droplet, the well was then sealed as normal. 
2.7.3. Co-crystallisation and crystal soaking 
In order to introduce substrate into the active site, samples were co-crystallised with L-kynurenine, or 
crystals were soaked in L-kynurenine solutions. Co-crystallisation was achieved by mixing pure protein 
sample with L-kynurenine solution to give a final concentration of 1 mM L-kynurenine prior to 
crystallisation. 
To soak crystals they were extracted from the hanging drop and soaked in a 1 μL drop of mother liquor 
stabilised with 25 % PEG 8K and supplemented with L-kynurenine (1 mM). The higher PEG 8K 
concentration ensured crystals did not dissolve. These were then returned to the sealed well for at least 
12 hours to allow substrate to enter the active site. 
2.7.4. Crystal mounting 
Crystals were extracted from their droplet using CrystalCap™ SPINE HT 0.1-0.2 mm Cryoloops. 
Where necessary crystals were cryogenically protected by dipping them sequentially in well solution 
containing 10 % ethylene glycol, then 20 % ethylene glycol. The crystals were flash cooled in liquid 
nitrogen, placed in a sample puck and shipped to Diamond Light Source synchrotron. 
2.7.5. Data collection 
Data were collected remotely from Diamond Light Source synchrotron. Crystals were screened by 
taking 4 images 90 ° apart, strategies were calculated using EDNA or Mosflm. The typical data 
collection parameters of a data set are shown in Table 2.5. 
Oscillation 0.05-0.15 ° 
Transmission 20-30% 
Exposure 0.05-0.2 seconds 
Resolution 1.2-2.0 Å 
Total oscillation 180-360 ° 
Table 2.5 Synchrotron collection parameters. 
2.8. Data Processing 
2.8.1. Model building 
Data processing was performed using the CCP4 program suite158. Images collected from the 
synchrotron were indexed, integrated, scaled and merged either by using iMosflm and Scala or using 
Xia2159-161. In all cases 5 % of reflections were used to make a FreeR test set. 
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Models were created from the resulting data using the molecular replacement program Molrep162. The 
original model used for molecular replacement in this thesis was 1 molecule of substrate bound dm2 in 
space group I4122 solved by Martin Wilkinson of the Mowat group143, 162. Water molecules were 
removed from the model before use, FAD and L-Kyn remained. Molrep employed non-crystallographic 
symmetry (NCS) of the original I4122 model to locate the second molecule within the asymmetric unit 
(ASU). 
Restrained refinement was carried out using Refmac5, alterations to models were made using Coot163, 
164. B-factors were modelled isotropically in all cases. Further calculations involving B-factors, such as 
averaging, was performed using all atoms. Neither NCS nor translation-libration-screw (TLS) 
modelling were used throughout refinement. Simple Wilson scaling was used for bulk solvent regions. 
FAD was inserted into each model using the Coot (version 0.7.2.1) library after the first refinement. 
Models were altered to decrease peaks in the DELFWT map and to adhere to structural considerations 
e.g., Ramachandran angles. Ramachandran angles were analysed using the Dynarama plug in of Coot. 
The underlying distributions of Ramachandran angles were taken from the Richardson 500165. Water 
molecules were introduced using Refmac5 where the DELFWT map was greater than 2 σ. These waters 
were checked for proximity to other atoms and their effect on the DELFWT map. Further water 
molecules were introduced manually using peaks in the DELFWT map as a guide. 
In L-Kyn exposed models, water molecules within the active site were removed to allow substrate to 
be modelled. L-Kyn was inserted into models using the Coot (version 0.7.2.1) library. L-Kyn was then 
manipulated to best fit the electron density within the active site. The torsion angles involving the planar 
ring allowed no deviation, the butanoic acid tail was allowed some variation with estimated standard 
deviation of 20°. 
Each dataset was evaluated on a number of factors. These factors included a high correlation coefficient 
(CC1/2), low Rmerge, a high I/σ(I), high completeness and high multiplicity. These were considered 
alongside the resolution of each structure and the quality of electron density, particularly around the 
area of interest. Only the best examples from the many datasets collected for each protein are presented 
in this work. 
2.8.2. Model Analysis 
Pymol was used to create images of the models166. Pymol was also used to create alignments of protein 
molecules167. The molecules were first aligned by residue using BLOSUM62 weightings168. The alpha 
carbon atoms (Cα) of aligned residues were matched, the molecules were superpositioned by 
minimising the root mean square deviation (RMSD) between matched atoms. The RMSD and number 
of Cα atoms aligned is recorded with each alignment. Fft was used to create Fo-Fc and 2Fo-Fc maps to 
display in images of the models158. 
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In order to assess the impact of crystal contacts upon the movement of the C-terminus the program 
NCONT was used169. The program was limited to only analyse from residue 370 to the C-terminal 
residue. The calculations included the other molecule within the ASU and any symmetry generated 
molecules. Any interactions within the molecule itself were discounted. The contacts reported were 
within 5.0 Å.  
Polder maps were employed to assess the likelihood of substrate occupancy using the program 
PHENIX170. An OMIT map is when a molecule, such as the substrate, is purposefully removed from a 
model. This model is then refined to create an Fo-Fc map that may show positive peaks in the region of 
the omitted molecule. This indicates the absence of electron density does not match the data. These 
simple OMIT maps do not take into account the contribution to electron density from the bulk solvent 
modelled across the structure. Polder maps are similar to OMIT maps but they remove this bulk solvent 
from the desired region and are therefore less biased by the solvent171. 
In order to validate these maps the correlation between three different polder maps are assessed. Map 1 
and 2 are calculated while map 3 is the actual experimental data. Map 1 is made assuming the omitted 
atoms are present; map 2 is made assuming the omitted atoms are not present. If map 3 shows the 
omitted atoms then it will correlate best to map 1. If map 3 shows only solvent then it will correlate best 
to map 2. 
Surface calculations were performed with the Pymol plugin KVfinder172. The surface calculations were 
to analyse the surface area and void volume of the active site of KMO, including the opening discussed 
in section 1.6.3. The calculations were based on the positioning of the L-Kyn molecule within the model 
of the closed molecule of substrate-bound dm2. A box (5.5 x 7.3 x 6.0 Å) was drawn surrounding L-Kyn 
to contain the calculation. The size of the box included the active site and extended beyond the 
narrowest part of the opening seen in Figure 3.17. Water molecules and substrate were deleted from the 
model prior to calculations. Calculations used a minimum cavity volume of 5 Å3, a step size of 0.6 Å, 
an inner probe radius of 1.4 Å and an outer probe radius of 5.0 Å. The total surface area and total void 
volume in the box are reported. 
For all other molecules the same size and position of box was necessary for comparison. This was 
achieved by first aligning the molecule in question to the closed molecule of substrate-bound dm2, as 
discussed earlier in this section. The box was drawn using the L-Kyn from the closed molecule of 




Chapter 3:  Structures of PfKMO dm2 
3.1. Introduction 
As previously discussed in section 1.6.2 the original crystals of PfKMO dm2 were grown using PEG 
4K as the precipitant, and the conditions are detailed in Table 3.1. 
Solution Concentration 
HEPES pH 7.0 0.1 M 
PEG 4K 15 % w/v 
Glycerol 10 % v/v 
Propan-2-ol 10 % v/v 
Dithiothreitol 2 mM 
L-kynurenine 1 mM 
Table 3.1 Conditions used to grow original crystals of dm2 and mutants. L-Kyn added only in the case where 
substrate-bound protein structures were desired.  
These conditions led to either P21221 crystals yielding a substrate-free structure with a maximum 
resolution of 2.26 Å or I4122 crystals yielding a substrate-bound structure with a maximum resolution 
of 3.24 Å. The I4122 crystals, in particular, had very high solvent content and very high B-factors overall. 
This clearly affected the quality and reliability of the resulting model. 
In these structures of dm2 there was a C-terminus movement observed between the substrate-bound and 
the substrate-free forms, and it was hypothesised that the presence of L-Kyn caused this. The two forms, 
however, were in different space groups. It is therefore possible that the C-terminus movement was 
being caused by changes in the crystal contacts. If the C-terminus was being forced closed by the 
presence of other molecules one would expect to see a high number of contacts in the closed conformer 
and a lower number in the open conformer. 
When mutant forms of dm2 were crystallised they showed a decreased movement in the C-terminus. 
The mutants still crystallised in the same space groups with P21221 crystals yielding substrate-free 
structures and I4122 crystals yielding substrate-bound structures. This occurrence seemed to refute the 
theory that crystal contacts caused the C-terminus shift. 
It could be argued, however, that the presence of L-Kyn caused the protein crystals to grow in the 
different space groups, thus creating different crystal contacts and inducing the C-terminus movement. 
Further analysis of the structures solved by Wilkinson was performed using NCONT143, 169. The program 
reported on the number of crystal contacts between the molecule in question, other protein molecules 
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in the ASU and symmetry generated molecules. Only residues after and including residue 370 were 
analysed for contacts closer than 5.0 Å. All internal contacts were discarded. The results are presented 
in Table 3.2. 
Molecule Total number of contacts 
Substrate-bound dm2 
Molecule A 287 
Substrate-free dm2 
Molecule A 332 
Molecule B 530 
Molecule C 491 
Molecule D 251 
Table 3.2 Total number of crystal contacts exhibited in dm2 structures grown in PEG 4K conditions. 
The number of crystal contacts varies greatly from molecule to molecule even when in the same ASU. 
The substrate-free molecules show a variation of more than double the contacts solely from positioning 
within the ASU and the unit cell as a whole. Despite this the molecules show almost identical 
positioning of the C-terminus when overlaid with one another, as shown in Figure 3.1. The number of 
contacts in the substrate-bound structure is also fewer than most of the substrate-free molecules. These 





Figure 3.1 Crystal structure of substrate free dm2 grown in PEG 4K conditions by Wilkinson143. Molecules from 
the ASU are overlaid. RMSD values were generated by aligning each molecule to molecule A (cyan). RMSD 
values of the overlays range from 0.458-0.730 Å, from at least 438 aligned Cα atoms in each case. 
Using new crystallisation conditions this chapter reports high-resolution structures of dm2 in both 
substrate-bound and substrate-free forms. Interactions between binding residues and L-Kyn are 
examined, as is the movement and putative bonding network between the C-terminus and the rest of the 
protein. 
3.2. Substrate bound dm2 crystal structure 
3.2.1. Protein purification 
The dm2 protein was expressed and purified as described in Chapter 2. An example of a typical 
chromatogram from both the Q Sepharose column and the Superdex 75 column are shown in Figure 3.2 




Figure 3.2 Typical chromatogram of absorbance at 280 nm of eluent from the Q Sepharose column against 
volume in ml. The column was pre-equilibrated with lysis buffer; the chromatogram shows when the protein 
sample and buffers were added to the column. For further details refer to section 2.4.1. 
 
Figure 3.3 Typical chromatogram of absorbance at 280 nm of eluent from the Superdex 75 column against 
volume in ml. The protein was collected by an automated fraction collector monitored by UV absorbance at 
280 nm. For further details refer to section 2.4.1. 
The fractions were tested for purity and concentration using absorbance measurements described in 
section 2.5.2 and pooled. SDS-PAGE was performed of samples from throughout the purification 




Figure 3.4 Typical SDS-PAGE gel of dm2 purification. novex® SeeBlue® Pre-Stained Standard was used as a 
marker (M); the weights of the standards are included in kiloDaltons (kDa). Lane 1 – Cell pellet of centrifuged 
lysed cells. Lane 2 – Supernatant of centrifuged lysed cells. Lane 3 – Pooled fractions of dm2 after the 
Q Sepharose column. Lane 4 – Pooled fractions of dm2 after the Superdex 75 column. 
The protein was concentrated by centrifugation to a concentration of 675 μM, confirmed by UV-Vis 
spectrophotometry, shown in Figure 3.5. 
 
Figure 3.5 UV-visible spectrum of 1:100 dilution of dm2. Concentration calculated from absorbance of 0.083 at 
450 nm with molar extinction coefficient (ε450) of 12,300 M-1 cm-1. 
The Michaelis-Menten kinetics of the dm2 was assessed using the assay outlined in section 2.6. The 
















 An example of a Michaelis-Menten plot is shown in Figure 3.6. 
 
Figure 3.6 Graph of a typical Michaelis-Menten plot for dm2 using L-Kyn as substrate, showing KM and kcat 
values. 
The resulting protein was deemed pure enough and presented an activity profile to allow crystallisation. 
3.2.2. Crystal growth and data collection 
New crystallisation conditions arose as part of an industrial collaboration173. The conditions were 
initially discovered from sparse matrix screen tests using the JCSG Core Suite III and the JCSG+ 
screens developed by the Joint Centre for Structural Genomics174, 175. These will be referred to as the 
PEG 8K conditions and are described in Table 3.3.  
Solution Concentration 
Na cacodylate pH 6.5 0.08 M 
PEG 8000 10-20 % w/v 
Ca acetate 0.16 M 
Glycerol 20 % v/v 
L-kynurenine 1 mM 
Table 3.3 Conditions used to grow improved crystals of dm2. L-Kyn added only for substrate-bound crystals. w/v 
is weight per volume, v/v is volume per volume. 
The new PEG 8K conditions were used to set up hanging drop trays as described in Chapter 2. Two 
trays were set up, one co-crystallised with 1 mM L-Kyn, the other without L-Kyn. Within 24 hours a 
number of large crystals had formed as seen in Figure 3.7. Selected crystals were then soaked in 1 μL 
drops comprising mother liquor stabilised with 25 % PEG8K and 1 mM L-Kyn. Crystals were then left 




Figure 3.7 Crystals of dm2 grown in PEG 8K conditions. The camera provided a 0.2 mm scale bar. 
Individual crystals were flash-cooled in liquid N2 as described in section 2.7.4 and sent to the Diamond 
Light Source. Using beamline i04-1 data were collected. Using Fast single data reduction pipeline 
software (FASTDP) the space group of all the crystals analysed was determined as P1211. The unit cells 
of the crystals, both substrate bound and substrate free, were all very similar; the approximate values 
are shown in Table 3.4. 
Crystal 
Parameter 
a b c β 
Approximate 
value 
70 Å 52 Å 138 Å 104° 
Table 3.4 Values of unit cell parameters for crystals grown in PEG8K conditions. 
 
Figure 3.8 Mounted crystal of substrate-exposed dm2 used for data collection. 
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From the crystal shown in Figure 3.8 1800 images were collected with beamline transmission 18.75 %, 
exposure of 0.05 s and oscillation of 0.10°. One of these images is shown in Figure 3.9. 
 
Figure 3.9 Diffraction image from dm2 crystal exposed to L-Kyn. 
The statistics shown in Table 3.5 were calculated using the programs iMosflm and Scala159, 160. 
Resolution (Å) Rmerge Mean (I)/σ(I) Completeness 
(%) 
Multiplicity 
67.8-1.5 0.062 8.1 99.7 3.1 
Table 3.5 Data collection statistics for a substrate-exposed dm2 crystal. All calculated from overall data, for full 
data collection statistics see Appendix 7.1.1. 
Molecular replacement was used to calculate structure factors. For further details see section 2.8. The 
structure was solved with two dm2 molecules in the ASU and a solvent content of 49.5%. As detailed 
in section 2.8, Refmac5 was used to carry out restrained refinement and Coot was used to edit the 




Figure 3.10 Crystal structure of substrate-bound dm2 showing both molecules in the ASU. Molecule A is 
coloured cyan, molecule B is coloured violet. 
3.2.3. FAD and Kynurenine Binding 
The first refinement of the model showed clear electron density for the FAD cofactor in both molecules, 
as shown in Figure 3.11. 
 
Figure 3.11 FAD bound in dm2 with the 2Fo-Fc map on the left in blue (contoured at 0.51 eÅ-3, 1.51 σ) and with 
the Fo-Fc map, calculated in the absence of FAD, on the right in green (contoured at 0.35 eÅ-3, 3.0 σ). 
The model contained residues 7-457 in molecule A and residues 7-456 in molecule B. Refmac5 was 
used towards the end of refinement to locate 1074 water molecules within the model. These were then 
manually removed from the active site of both molecules to investigate the presence of ligand electron 
density. When refined once more there was clear electron density matching the shape of L-Kyn in 
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molecule A. The other molecule showed less definitive evidence of L-Kyn binding, and this could only 
be visualised at low levels of contouring. Both active sites can be seen in Figure 3.12. 
 
Figure 3.12 L-Kyn modelled in the binding site of dm2 a. 2Fo-Fc map for molecule A b. Fo-Fc map for molecule 
A c. 2Fo-Fc map for molecule B d. Fo-Fc map for molecule B. 2Fo-Fc maps are shown in blue (contoured at 0.51 
eÅ-3, 1.51 σ). Fo-Fc maps, calculated in absence of L-Kyn, are shown in green (contoured at 0.35 eÅ-3, 3.0 σ). 
The final model was refined to give R and Rfree values of 0.2328 and 0.2715, respectively, to a resolution 
of 1.5 Å. The full statistics can be seen in Appendix 7.1.1. 
3.2.4. Comparison of new and old dm2 structures 
The previously solved substrate-bound dm2 model, grown in PEG 4K conditions, was compared to 
molecule A of the new model. This was done using RMSD as detailed in section 2.8. Both are very 
similar overall (RMSD = 1.492 Å from 450 aligned Cα atoms), with FAD placement almost identical 




Figure 3.13 Overlaid crystal structures of substrate bound dm2 grown in original and improved conditions. 
Original molecule shown in green, molecule A of improved PEG 8K conditions shown in cyan. FAD is shown in 
yellow, L-Kyn is shown in orange. RMSD = 1.492 Å from 450 aligned Cα atoms. 
The positioning of the L-Kyn within the active site of the new structure is shown in Figure 3.14. There 
are small differences in the protein-ligand interactions between this structure and the original dm2 




Figure 3.14 a. Crystal structure of active site of dm2 bound with L-Kyn, molecule A. b. Chemdraw schematic of 
dm2 bound with L-Kyn. Distances between atoms are in Å and shown as red dashed lines. The site of oxidation 
is denoted with an asterisk (*). 
In this model L-Kyn is shown to form H-bonds with many of the same residues as previously seen. For 
example the FAD carbonyl to L-Kyn’s aromatic amine and the N369 to the carboxylic acid interactions 
are the same, with similar distances between the groups. R84 shows similar interactions to those 
observed in previous structures. The positive guanidinium group of R84 forms an electrostatic 
interaction with the negative carboxylate group of L-Kyn, implying a stronger interaction than with the 
other binding residues. L-Kyn’s aliphatic amine forms H-bonds between H320 and Y404, neither of 
which were seen in previous models. In contrast, in this structure Y98 is too far from the substrate to 
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show a direct interaction. Instead both the hydroxyl of Y98 and the carboxylate of L-Kyn form an 
H-bond to the same water molecule. There is a water molecule seen in the same relative position in both 
molecules of the ASU. A water molecule is also seen interacting with the carboxylate; an equivalent 
water molecule is present in the other protein molecule. The hydrophobic residues within the active site, 
such as I224 and F238, form a lipophilic area surrounding the aromatic ring of L-Kyn (not pictured). 
The overall position of L-Kyn allows for it to react with the flavin-C4a-hydroperoxide group once it 
has formed. 
This model reinforces R84 as a key-binding residue and further highlights the importance of Y404. The 
role of Y98 is proposed to be less influential than assumed from previous models. 
3.2.5. Comparing substrate bound dm2 molecules within the asymmetric unit 
Comparing the active site within the two molecules in Figure 3.15 there is very little difference in 
positioning of residues. There is a small difference in R84 positioning between the two molecules. This 
may be influenced by the electrostatic interaction with the substrate, pulling the side chain into position.  
 
Figure 3.15 Crystal structure of dm2 with L-Kyn bound, showing overlaid active sites of molecule A (cyan) and 
molecule B (violet). RMSD = 1.165 Å from 436 aligned Cα atoms. 
The active sites of both molecules within the ASU of the PEG 8K crystals are the same within 
experimental error. There are, however, large differences between the two molecules overall. In the 
I4122 form only one molecule was present in the ASU, with 100% occupancy of substrate. In the P1211 
form the occupancy of substrate differs significantly between the molecules in the ASU, as seen in 
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Figure 3.12. The molecules themselves also differ. When overlaid with one another, molecules A and 
B of the P1211 dm2 show a familiar movement of the C-terminal domain, despite a low RMSD. This is 
shown in Figure 3.16. 
 
Figure 3.16 Crystal structure of dm2 bound with L-Kyn, molecules A and B overlaid with one another. Molecule A 
is shown in cyan, molecule B is shown in violet. RMSD = 1.165 Å from 436 aligned Cα atoms. 
The C-terminal movement matches the movement discussed in section 1.6.3 purportedly caused by the 
presence of L-Kyn. Molecule A matches with the closed conformation, while molecule B matches the 
open conformation. Interestingly the occupancy level of substrate matches with these positions, the 
closed molecule A shows high occupancy of substrate, while the open molecule B shows very low 
occupancy of substrate. The channel leading to the active site is also seen in the open position, as shown 
in Figure 3.17. This would allow L-Kyn to diffuse in and out of the enzyme, explaining its low 
occupancy level. The access route is shut in closed molecule A, causing L-Kyn to remain trapped in the 





Figure 3.17 Crystal structure of dm2 bound with L-Kyn showing surfaces. Molecule A is shown in cyan on the 
left, molecule B is shown in violet on the right. The C-terminus is shown in darker shade. An enlarged view of the 
ligands is also shown. 
Surface calculations were performed on the two molecules using the program KVFinder172. The results 
are shown in Table 3.6. 
 Void Volume (Å3) Surface Area (Å2) 
Closed molecule 376 413 
Open molecule 374 431 
Table 3.6 Values of surface calculations of substrate-bound dm2. 
The volume of the active site seems very similar for both molecules. The surface area, however, is 
shown to be slightly larger in the open molecule. This is to be expected since there is a larger opening 
seen in the open molecule. 
A slight movement between the two molecules is also observed in the bottom right of Figure 3.16, 
corresponding to residues 240-290. The B-factors of these residues are consistently higher than the 
mean indicating they are more mobile than the overall structure. It is possible that their movement is 
linked to the movement of the C-terminus. Given this is the first observation of this movement its 
relevance to the open and closed conformations cannot be commented on until we examine more 
structures. This movement is not seen in the previous models grown in PEG 4K conditions. The residues 
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in question do not seem involved in the active site, nor the opening of the channel shown in Figure 3.17. 
They have also never been recognised in previous literature as important.  
3.3. Substrate free dm2 crystal structure 
3.3.1. Crystal growth and data collection 
Having been expressed and purified as detailed in section 3.2.2, dm2 was crystallised using the PEG 
8K conditions but at no point was the enzyme exposed to L-Kyn. Individual crystals were flash-frozen 
in liquid N2 and sent to the Diamond Light Source. Using beamline i02 data were collected. Using 
FASTDP the space group of all the crystals analysed was determined as P1211 with the same 
approximate unit cell dimensions as detailed in Table 3.4. From the crystal shown in Figure 3.18 2000 
images were collected with beamline transmission 20.00 %, exposure of 0.05 s, and oscillation of 0.10°. 
 
Figure 3.18 Mounted crystal of substrate free dm2 used for data collection. 
The statistics shown in Table 3.7 were calculated using iMosflm and Scala159, 160. 
Resolution 
(Å) 
Rmerge Mean (I)/σ(I) Completeness 
(%) 
Multiplicity 
67.76-1.79 0.047 14.3 99.6 3.4 
Table 3.7 Data collection statistics for a substrate-bound dm2 crystal. All calculated from overall data, for full data 
collection statistics see Appendix 7.1.1. 
Molecular replacement was used to calculate structure factors. For further details see section 2.8. The 
structure was solved with 2 molecules in the ASU and a solvent content of 48.06%. As detailed in 
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section 2.8, Refmac5 was used to carry out restrained refinement and Coot was used to edit the model163, 
164. Both molecules within the model contain residues 6-461. 532 waters were located using Refmac5 
and the R and Rfree values of the final model were 0.1692 and 0.2080, respectively, to a resolution of 
1.79 Å. The full statistics can be found in Appendix 7.1.1. An overall image of the model is shown in 
Figure 3.19. 
 
Figure 3.19 Crystal structure of substrate-free dm2 showing both molecules in the ASU. Molecule A is coloured 
orange; molecule B is coloured green. 
3.3.2. Overall structure of substrate free dm2 
The most immediate finding is that the two molecules also exhibit open and closed positions. There is 
a very similar shift in the C-terminal domain to that observed in the substrate-bound model, as shown 




Figure 3.20 Crystal structure of L-Kyn free dm2, molecules A and B overlaid with each other. RMSD = 1.028 Å 
from 444 aligned Cα atoms. 
The channel opening and closing is also observed, as shown in Figure 3.21. The closed position of 
molecule A shows a very slight opening to the active site whereas the open molecule B shows a channel 





Figure 3.21 Crystal structure of L-Kyn free dm2, showing surfaces. Molecule A is shown in orange on the left, 
molecule B is shown in green on the right. The C-terminus is shown in lighter shade. An enlarged view of the 
ligands is also shown. 
As with the substrate-bound model, surface calculations were performed on the active site of each 
molecule. The results are shown in Table 3.8. 
 Void Volume (Å3) Surface Area (Å2) 
Closed molecule 383 448 
Open molecule 322 382 
Table 3.8 Values of surface calculations of substrate-free dm2. 
These results are contradictory to our expectations of the more open molecule having a larger surface 
area or void volume in the active site. These findings, as well as the appearance of a small opening in 
the closed molecule, may indicate a more fluid transience between conformations. 
In the PEG 8K conditions the similarity, in terms of crystal symmetry and unit cell dimensions, between 
the substrate bound and substrate free forms of dm2 allows for a better comparison than previously 





Figure 3.22 Crystal structures of dm2. L-Kyn bound dm2 is shown in cyan and violet, L-Kyn free dm2 is shown is 
orange and green. Molecules A are shown on the left with RMSD = 0.514 Å from 438 aligned Cα atoms. 
Molecules B are shown on the right with RMSD = 0.731 Å from 445 aligned Cα atoms. 
The equivalent molecules of both crystals align very closely with one another, with small RMSD values. 
The C-termini for both pairs of molecules are in very similar positions. This shows that dm2 is in both 
the open and closed conformations regardless of substrate exposure. The fact that dm2 is able to take 
up the closed position in the absence of L-Kyn contradicts the hypothesis that the C-terminus shift is 
solely controlled by the presence of substrate. 
The crystal contacts of the structures presented in the chapter were analysed with NCONT as discussed 
in section 2.8.1. The results are shown in Table 3.9. 
Molecule Total number of contacts 
Substrate-bound dm2 
Open molecule 344 
Closed molecule 317 
Substrate-free dm2 
Open molecule 437 
Closed molecule 443 
Table 3.9 Total number of crystal contacts exhibited in dm2 structures grown in PEG 8K conditions. 
Much like the crystal contact analysis in section 3.1; the number of contacts does not seem to affect the 
positioning of the C-terminus. In the substrate-bound structure the open molecule has much more 
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contacts, whereas the substrate-free structure shows slightly more contacts in the closed molecule. This 
continues the trend of the number of contacts bearing no relation to the positioning of the C-terminus. 
The movement of residues 240-290 is also observed in Figure 3.15 and is similar to that seen in the 
substrate-bound structure. The residues align to each other in Figure 3.22, much like the C-terminus. 
This implies that the movement of these residues is connected to the movement in the C-terminus. The 
movement to the closed conformation may cause residues 240-290 to move to accommodate the change. 
If this were a necessary movement, however, it would be expected to occur in the previous models 
grown in PEG 4K conditions. The link, therefore, remains unclear but their putative connection will be 
scrutinised further throughout this work. The reasoning for observing specifically residues 240-290 is 
because they denote the most mobile residues of this section of the protein. Outwith these residues the 
movement of residues observed between molecules is minimal. 
When comparing the active sites of the two substrate-free molecules we see very little difference; much 
like the substrate-bound model in section 3.2.5. This is shown in Figure 3.23. 
 
Figure 3.23 Crystal structure of substrate-free dm2, showing overlaid active sites of molecule A (orange) and 
molecule B (green). RMSD = 1.028 Å from 444 aligned Cα atoms. 
Residues within the active site of equivalent molecules from both substrate-free and substrate-bound 




Figure 3.24 Crystal structure of overlaid molecules A from substrate-free and substrate-bound dm2, showing the 
active site. Substrate-bound dm2 is shown in cyan, substrate-free dm2 is shown in orange. RMSD = 0.514 Å 
from 438 aligned Cα atoms. 
The similarity between the two molecules within each crystal allows us to observe that all four 
molecules, both substrate-bound and -free, have very similar positioning of binding residues. The lack 
of difference, especially in residue R84 given its potential role within the C-terminus movement, implies 
the absence of any induced fit causing the enzyme to change conformation. This adds to the theory that 
L-Kyn is not responsible for the shift in the C-terminus. 
3.4. C-terminus movement 
The above findings do not diminish the importance of the C-terminus in substrate binding. The highest 
occupancy of L-Kyn is observed in a molecule when it is in the closed conformation. This section 
discusses the positioning of the residues identified as having a role in the possible bonding network 
between the C-terminus and the rest of the protein. 
The C-terminus of dm2 is relatively mobile as shown by its high B-factors. In order to compare 
B-factors the mean B-factors for all atoms in residues 370-400 of each molecule were divided by the 
mean B-factor for all atoms in whole structure. This is therefore an indication of relative mobility in 
residues 370-400 compared to the mobility of the overall structure. The residues 370-400 were chosen 
as they bookend the most mobile region of the C-terminal domain. Residue 370 is at the end of a 
relatively immobile α-helix and the start of a flexible loop. At residue 400 the B-factor value drops 
significantly as proximity to the active site increases, indicating the end of the mobile region. The values 
of this calculation for each molecule in both substrate-bound and substrate-free forms of dm2 are shown 




Molecule Mean B-factor of C-terminus/Mean B-factor of structure 
Bound closed (A) 1.2 
Bound open (B) 1.9 
Free closed (A) 1.3 
Free open (B) 1.8 
Table 3.10 Average B-factor for the residues 370-400 of substrate-free and substrate-bound forms of dm2 
divided by average B-factor of overall structure. 
In both of the models the open conformation has a higher average B-factor in the C-terminus. This 
implies that the open form is more mobile and disordered when compared to the closed form. When 
comparing the molecules within each ASU the substrate-free molecules are slightly closer in mobility 
than their substrate-bound counterparts. This could be connected to the presence of an interacting 
network between the C-terminus and the rest of the protein stabilising the closed form. It may also 
imply that the presence of L-Kyn strengthens this network, as discussed in section 1.6.3.  
Figure 3.25 is of substrate-bound molecule A; it shows the residues identified in chapter 1 as important 
in forming an interactive network. 
 
Figure 3.25 Crystal structure of putative C-terminus interactive network of substrate-bound dm2, molecule A in 
the closed conformation. 2Fo-Fc map is shown in blue (contoured at 0.34 eÅ-3, 1.0 σ) Distances between atoms 
are in Å and shown as red dashed lines. 
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The interactions between the residues shown are significantly decreased when compared to the initial 
models discussed in section 1.6.3. Only residues R84, Y382 and R386 are close enough to interact, and 
these distances would only imply very weak interactions. The electron density surrounding residues 
Y382 and R386 is also quite sparse. The average B-factors of the residues are 64.2 Å2 and 49.5 Å2, 
respectively; much higher than the average B-factor for the whole molecule of 35.1 Å2. This is 
interpreted as indicating that these residues in particular are very mobile. This is also seen in the other 
molecules of dm2, as shown in Figure 3.26. 
 
Figure 3.26 Crystal structure showing residues involved in the putative interacting network of the C-terminus of 
dm2 a. Closed molecule of L-Kyn bound dm2 b. Open molecule of L-Kyn bound dm2 c. Closed molecule of 
L-Kyn free dm2 d. Open molecule of L-Kyn free dm2. 2Fo-Fc maps are shown in blue (L-Kyn bound molecules 
contoured at 0.34 eÅ-3, 1.0 σ, L-Kyn free molecules contoured at 0.32 eÅ-3, 1.0 σ). Distances between atoms are 
in Å and shown as red dashed lines. 
From all the residues shown in Figure 3.26 only one interatomic distance is seen that would imply 
interaction. That is between E372 and Y382 in the open molecule B of substrate free dm2. The distances 
measured between the other residues are too large for them to be interacting. Despite the high resolution 
and low overall B-factor values of each molecule the electron density surrounding these residues, in 
particular R386 and Y382, is very limited. This implies that the mobility of these residues is very high. 
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While this does mean that the exact positioning of the residues is difficult to pinpoint, the high mobility 
itself shows that there is no obvious network of interactions between the residues. If strong interactions 
were present the residues would be expected to be held in place by them, and the B-factors considerably 
lower. This matches with the B-factors exhibited in Table 3.10, as distances between these residues 
increase the B-factors increase accordingly. This reasoning is somewhat indirect and the questions 
surrounding the mechanistic importance of the C-terminus would benefit from further directed study. 
Another confusing factor in the analysis of the movement of the C-terminus is the surface calculation 
data of the active site and channel opening. The expected pattern would be the closed molecule having 
a lower void volume and surface area. The results presented in this chapter counter this expectation, 
particularly the results of the substrate-free model, seen in Table 3.8. Further surface calculations are 
required of the other PfKMO variants before a hypothesis can be suggested. These are discussed in 
chapter 5. 
3.5. Summary 
Throughout this chapter a new crystal form of dm2, grown using PEG 8K conditions, has been 
examined. Thanks to a consistent space group between substrate-free and substrate-bound crystals 
comparisons between the two have been made easier. Interactions between L-Kyn and the active site 
have been recognised and now require further probing to establish their importance. Movement of the 
C-terminus has been shown to be essentially unaffected by presence or absence of substrate and both 
open and closed conformers of dm2 are present in each crystal. It has also been shown that crystal 
contacts do not have an effect upon the position of the C-terminus. The surface area and void volume 
of the dm2 active site does not appear to show any correlation between the closed and open conformers. 
Movement in residues 240-290 has been observed for the first time and is posited to have a connection 
to the open and closed conformations.  Very little evidence has been seen of an interactive network 
within the C-terminus. In light of all these finding the role of the C-terminus, in terms of dm2’s 
mechanism, is still to be established. The importance of the residues within this putative interactive 




Chapter 4:  Binding residues 
Certain residues within the active site of dm2 have been previously identified by M. Wilkinson as 
important for the binding of L-Kyn143. These residues have been described in Chapters 1 and 3 and their 
importance has been identified through structural analysis of dm2. The interactions were then 
investigated by H. Bell by creating a number of substitution mutations within the active site of dm2, 
followed by kinetic analysis of these mutants156. The Y404F mutation was introduced as it was a 
conservative substitution and allowed for the investigation of the H-bond between Y404 and L-Kyn. In 
the original model of dm2 the distance between substrate and Y404 had appeared to be too great to 
allow an H-bond. The removal of H-bond capability would determine the effect that Y404 interactions 
have upon substrate binding. The R84K mutation was also conservative given the similar size and 
positive charge on both residues. This would allow for investigation of the importance of interaction 
between substrate and R84. The contribution of N369 in substrate binding was also investigated with 
an N369S mutation. An H320F mutant was also produced since the mutation gives the protein an 
entirely analogous active site (in terms of sequence and likely structure) to that of hKMO, as seen in 
Figure 1.10. This allows for a closer structural representation of hKMO than previously seen. 
 The Michaelis-Menten kinetic data for the mutant forms of dm2 are shown in Table 4.1. 
Enzyme KM (μM) kcat (s-1) kcat/KM (μM-1 s-1) 
dm2 8.8 ± 1.5 8.9 ± 1.1 1.01 
Y404F 96.5 ± 4.0 6.2 ± 0.1 0.06 
R84K 0.0 0.0 0.0 
N369S 27.7 ± 3.3 4.5 ± 0.2 0.16 
H320F 18.0 ± 1.2 7.1 ± 0.2 0.39 
Table 4.1 Summary of Michaelis-Menten kinetic data for mutant forms of dm2. R84K exhibits no activity and is 
reported as zero156. 
The kinetic data for the mutant forms of dm2 described in Table 4.1 requires structural rationalisation. 
While structures of the mutants have already been solved the crystals were formed using the old PEG 
4K conditions. This meant that substrate-free and substrate-bound forms were in different space groups 
making comparisons more difficult. The resolution of these structures, especially the substrate-bound 
forms, was very low. The highest resolution for the substrate-bound models never exceeded 3.9 Å and 
the structure of a substrate-bound R84K mutant was never obtained. Using the new PEG 8K conditions 
the resolutions of these structures were greatly improved. This chapter presents the structures of the 
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dm2 mutants R84K, Y404F and H320F. Y404F has a ~ 30% reduction of kcat value but has a KM 10-fold 
greater than that of dm2. This implies Y404 is an important residue involved in substrate binding. R84K 
exhibited no activity whatsoever, implying it also is involved in substrate binding or mechanism. The 
change in kinetic parameters for N369S was not considered great enough to be a priority for structural 
rationalisation. The slight increase in KM may be accounted for in the size difference between Asn and 
Ser. The H-bonding group of Ser may be too far from L-Kyn to form a meaningful interaction in N369S. 
H320F, on the other hand, was investigated given its sequence similarity with hKMO, as previously 
mentioned. 
4.1. Substrate bound R84K dm2 
4.1.1. Crystal growth and data collection 
R84K dm2 protein was expressed and purified as described in Chapter 2 using the plasmid created by 
H. Bell156. The protein was concentrated to 300 μM, confirmed by UV-Vis spectrophotometry as shown 
in Figure 4.1. 
 
Figure 4.1 UV-visible spectrum of 1:100 dilution of R84K. Concentration calculated from absorbance of 0.037 at 
450 nm with ε450 of 12,300 M-1 cm-1. 
The new PEG 8K conditions were used to set up hanging drop trays as described in Chapter 2. Two 
trays were set up, one co-crystallised with 1 mM L-Kyn, the other without L-Kyn. Within 24 hours a 
number of large crystals had formed. Selected crystals were then soaked in 1 μL drops comprising 
mother liquor stabilised with extra PEG 8K and 1 mM L-Kyn. Crystals were then left for a further 24 

















beamline i04-1 data were collected. All crystals exhibited P1211 spacegroup with similar parameters to 
those seen in Table 3.4. 
 
Figure 4.2 Mounted crystal of substrate-exposed R84K used for data collection. 
From the crystal shown in Figure 4.2 1800 images were collected with beamline transmission 18.75 %, 
exposure of 0.05 s and oscillation of 0.15°. The statistics shown in Table 4.2 were calculated using the 
programs iMosflm and Scala159, 160. 
Resolution (Å) Rmerge Mean (I)/σ(I) Completeness 
(%) 
Multiplicity 
68.20-1.70 0.046 10.9 94.5 2.9 
Table 4.2 Data collection statistics for a substrate-bound R84K crystal. All calculated from overall data, for full 
data collection statistics see Appendix 7.1.2. 
Refinement and model editing were performed as for dm2, described in section 2.8. The structure was 
solved with two molecules in the ASU and a solvent content of 49.4%. An overall image of the two 





Figure 4.3 Crystal structure of substrate-exposed R84K showing both molecules in the ASU. Molecule A is 
coloured cyan, molecule B is coloured violet. 
4.1.2. Discussion of substrate-bound R84K dm2 structure 
The model showed both molecules with residues 6-457 and contained 659 waters in the ASU. The final 
model was refined to give R and Rfree values of 0.1655 and 0.1966, respectively, to a resolution of 1.70 
Å. The full statistics can be seen in Appendix 7.1.2. 
When comparing the two molecules within the ASU a difference in structure is observed in the 
C-terminus and residues 240-290, as shown in Figure 4.4. These follow the movements discussed in 




Figure 4.4 Crystal structure of substrate-bound R84K showing both molecules overlaid with one another. 
Molecule A is coloured cyan, molecule B is coloured violet. L-Kyn is coloured orange. RMSD = 0.937 Å from 445 
paired Cα atoms. 
Molecule Mean B-factor of C-terminus/Mean B-factor of structure 
Closed 1.1 
Open 1.6 
Table 4.3 Average B-factor for residues 370-400 of substrate-bound R84K divided by average B-factor of overall 
structure. 
The overall structures of R84K and dm2 are very similar, with an RMSD of less than an ångström. The 
absence of R84 does not appear to affect the movement of the C-terminus given that the positional shift 
is similar and the relationship between B-factors of the two molecules are similar to dm2, as shown in 




Figure 4.5 Crystal structures of substrate-bound R84K and substrate-bound dm2 overlaid, showing residue 84. 
RMSD = 0.573 Å from 447 aligned Cα atoms. R84K is shown in cyan, dm2 is shown in green, 2Fo-Fc map is 
shown in blue (contoured at 0.47 eÅ-3, 1.50 σ).  
Firstly there is a difference in structure for lysine only allows monodentate interaction, unlike the 
guanidinium of arginine. R84 has previously shown bidentate interaction with L-Kyn in the original 
model shown in Figure 1.25. Secondly the positioning of K84 points the residue away from the substrate, 
meaning there can be no interaction between L-Kyn’s acid group and the lysine’s amine. The resulting 





Figure 4.6 a. Crystal structure of active site of R84K bound with L-Kyn, molecule A. b. Chemdraw schematic of 
R84K bound with L-Kyn. Distances between atoms are in Å and shown as red dashed lines. The site of oxidation 
is denoted with an asterisk (*). 
There are a number of differences between the substrate binding sites of R84K, shown here, and dm2, 
shown in Figure 3.14. First of all, the distance from residue 84 to substrate is now over 8 Å, which 
implies no interaction. In addition to this, N369 is also too far from the substrate to form a significant 
interaction. Y404 is within H-bonding distance but now interacts with the acid group of L-Kyn, rather 
than the amine. The acid group of L-Kyn has rotated 90° due to the absence of R84 and in order to form 
a bond with Y404. Y98 still forms an H-bond to a water molecule but the distance and direction of the 
L-Kyn acid group relative to this water rules out any meaningful interaction. 
The reduced interaction with L-Kyn implies a reduced binding affinity for the enzyme; this in turn 
results in a lower occupancy of substrate. The presence of substrate in R84K is much less than in dm2, 




Figure 4.7 Crystal structure of substrate-bound R84K showing L-Kyn. 2Fo-Fc map is shown in blue (contoured at 
0.31 eÅ-3, 1.00 σ) 
The electron density surrounding L-Kyn is sparse when contoured to the same level as dm2, the 
contouring was therefore decreased. This shows the map surrounding the atoms with highest electron 
density, as would be expected. The electron density surrounding the amino acid group in particular 
supports the presence and positioning of L-Kyn rather than only water molecules being present within 
the active site. L-Kyn is modelled within the structure with an occupancy of 100 %; this also supports 
the conclusion that L-Kyn is bound, if somewhat weakly, within the molecule. This is discussed further 
in section 4.2.2. 
The interruption in interactions between L-Kyn and certain binding residues cannot in itself explain the 
total loss of activity seen in R84K. However, when comparing the substrate molecules of R84K and 
dm2 a reason can be suggested.  
 
Figure 4.8 Crystal structure of R84K showing L-Kyn overlaid with L-Kyn of dm2. R84K is shown in orange, dm2 
is shown in green. Distances between atoms are in Å and shown as red dashed lines. RMSD = 0.573 Å from 447 
aligned Cα atoms. 
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When compared in Figure 4.8 the relative position of the modelled L-Kyn in dm2 and R84K has 
changed. The molecule has moved 2.5 Å away from N369 and Y404. dm2 shows all of L-Kyn below 
the plane of the isoalloxazine of FAD whereas in R84K the aromatic amine of L-Kyn is in line with the 
plane. This change in position is enough to rationalise the inactivity of the enzyme, since its position in 
relation to the FAD may no longer allow for a reaction with the hydroperoxide intermediate to occur. 
4.2. Substrate-free R84K dm2 
4.2.1. Crystal growth and data collection 
Using the protein prepared in section 4.1 new crystal trays were prepared using the same method as 
described in section 4.1.1 with no exposure to L-Kyn. These substrate-free crystals were sent to 
Diamond Light Source. Using beamline i03 data were collected. 
 
Figure 4.9 Mounted crystal of substrate-free R84K used for data collection. 
From the crystal shown in Figure 4.9 2000 images were collected with beamline transmission 100 %, 
exposure of 0.1 s and oscillation of 0.1°. The statistics shown in Table 4.4 were calculated using the 
programs iMosflm and Scala159, 160. 
Resolution 
(Å) 
Rmerge Mean (I)/σ(I) Completeness 
(%) 
Multiplicity 
67.95-1.80 0.113 4.6 98.3 2.7 
Table 4.4 Data collection statistics for a substrate-free R84K crystal. All calculated from overall data, for full data 
collection statistics see Appendix 7.1.2. 
Refinement and model editing were performed as for dm2, described in section 2.8. The structure was 
solved with 2 molecules containing residues in the ASU and a solvent content of 49.2 %. Each molecule 
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contained residues 6-457 and a total of 614 waters were modelled in the ASU. The final model was 
refined to give R and Rfree values of 0.1879 and 0.2283, respectively, to a resolution of 1.80 Å. The full 
statistics can be seen in Appendix 7.1.2. 
4.2.2. Discussion of substrate-free R84K dm2 structure 
The overall structure of substrate-free R84K is similar to the substrate-bound form of R84K. There is 
however a difference in the shift of the C-terminus, as seen in Figure 4.10. 
 
Figure 4.10 Crystal structure of substrate-free R84K, showing both molecules overlaid with one another. 
Molecule A is coloured orange, molecule B is coloured green. RMSD = 0.582 Å from 447 aligned Cα atoms. 
Molecule Mean B-factor of C-terminus/Mean B-factor of structure 
A 1.5 
B 1.8 
Table 4.5 Average B-factor for residues 370-400 of substrate-free R84K divided by average B-factor of overall 
structure. 
There is very little movement of the C-terminus seen between the two molecules. The average B-factor 
of the residues within the C-terminus are shown in Table 4.5. Given the lack of a clear open or closed 
molecule it is difficult to claim the numbers follow the trend of the closed molecule having the lower 
B-factor. When compared to the substrate-bound molecules the substrate-free C-termini are in between 
the closed and open position. 
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The decreased movement of the C-terminus was seen in other substrate-free R84K crystals. This is 
therefore not an occurence in one crystal. Some crystals showed the two molecules to be similar enough 
to only assign one molecule within the ASU, with the unit cell halved in length. 
Interestingly the movement in residues 240-290 is also minimilised. This supports the link between the 
two sections; since the C-terminus is not moving, residues 240-290 no longer need to accommodate 
said movement. 
The position of K84 in all four molecules is shown in Figure 4.11.  
 
Figure 4.11 Crystal structure of R84K molecules, showing residue K84 from both molecules of substrate-bound 
and substrate-free structures. RMSD values were generated by aligning each molecule to the “closed” 
substrate-bound molecule (cyan). RMSD values of the overlays range from 0.729 – 0.965 Å, from at least 439 
aligned Cα atoms in each case. 
The active sites within all four molecules of both the substrate-bound and substrate-free crystals are 
very similarly positioned. Much like dm2 the binding residues are not seemingly affected by the 
presence or absence of L-Kyn. 
In order to provide further evidence of L-Kyn occupancy in the substrate-exposed structure the Fo-Fc 
maps of the substrate-exposed structure and the substrate-free structure were compared. This is to 
counter the possibility that the electron density is only water molecules. L-Kyn and water molecules 
were deleted from the active sites of the structures and these models were refined using Refmac5164. 




Figure 4.12 Crystal structures of R84K showing the active site. a. Substrate-exposed R84K with Fo-Fc map 
(contoured at 0.31 eÅ-3, 3.00 σ) b. Substrate-free R84K with Fo-Fc map (contoured at 0.31 eÅ-3, 3.00 σ). 
The Fo-Fc maps shown in Figure 4.12 show a clear difference in occupancy levels between the two 
structures. This supports the presence of the L-Kyn in the substrate-exposed structure, if the active site 
had only water molecules present we would expect to see similar peaks in the Fo-Fc map of the 
substrate-free structure. 
There is also the possibility that the electron density modelled in Figure 4.7 is caused by acetate or 
glycerol, both of which are present in the crystallising well solution. These small molecules are used in 
the well solution for both substrate-exposed and substrate-free crystals. One would, therefore, expect to 
see the same levels of acetate and glycerol in both crystal structures. There is, however, an absence of 
any significant electron density within the substrate-free protein in Figure 4.12. This indicates the 
difference in electron density between the two structures at the active site is caused by weakly bound 
L-Kyn. 
The use of polder maps was also implemented to assess the presence of L-Kyn. The substrate molecule 
was selected for omission and a polder map was created using Phenix170, 171. The three maps were then 
compared using correlation coefficients; see section 2.8.2 for details. 
Maps being compared Local correlation coefficient Peak correlation coefficient 
1, 2 0.69 0.76 
1, 3 0.81 0.76 
2, 3 0.68 0.72 
Table 4.6 Correlation coefficients of polder map calculations for substrate-bound R84K. 
The correlation is greatest between maps 1 and 3 the polder map, supporting the presence of L-Kyn. 
However, the similar values of peak correlation coefficients require consideration and imply that these 
results are insufficient to decide whether the density belongs to ligand or bulk solvent171. These findings, 
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if used in isolation would not allow for strong conclusions. The results can, however, be added to the 
other supporting factors, such as the Fo-Fc maps and the high ligand occupancy. The use of all these 
data bolsters the argument for the presence of a weakly bound substrate but cannot definitively confirm 
it. 
The findings of this section matches with previous work by Mole et al., Amaral et al. and Bell in 
highlighting the importance of residue R8411, 140, 156. This brings a structural rationalisation to the 
inactivity seen in R84K PfKMO and the drop in activity in the equivalent R83 mutants of ScKMO. 
4.3. Substrate-bound Y404F dm2 
4.3.1. Crystal growth and data collection 
Y404F dm2 protein was expressed and purified as described in Chapter 2 using the plasmid created by 
H. Bell156. The protein was concentrated to 350 μM confirmed by UV-Vis spectrophotometry, as shown 
in Figure 4.13. 
 
Figure 4.13 UV-visible spectrum of 1:100 dilution of Y404F. Concentration calculated from absorbance of 0.043 
at 450 nm with ε450 of 12,300 M-1 cm-1. 
The new PEG 8K conditions were used to set up hanging drop trays as described in Chapter 2. Two 
trays were set up, one co-crystallised with 1 mM L-Kyn, the other without L-Kyn. Crystals formed 
within 24 hours. Selected crystals were then soaked in 1 μL drops comprising of mother liquor stabilised 
with extra PEG 8K and 1 mM L-Kyn. After a further 24 hours individual crystals were flash cooled in 
liquid N2 and sent to the Diamond light source. Data were collected using beamline i04-1. All crystals 

















Figure 4.14 Mounted crystal of substrate-exposed Y404F used for data collection. 
From the crystal shown in Figure 4.14 1800 images were collected with beamline transmission 18.75 %, 
exposure of 0.05 s and oscillation of 0.15°. The statistics shown in Table 4.7 were calculated using the 
programs iMosflm and Scala159, 160. 
Resolution (Å) Rmerge Mean (I)/σ(I) Completeness 
(%) 
Multiplicity 
68.20-1.80 0.069 8.4 96.0 3.1 
Table 4.7 Data collection statistics for a substrate-bound Y404F crystal. All calculated from overall data, for full 
data collection statistics see Appendix 7.1.3. 
Refinement and model editing were performed as for dm2, described in section 2.8. The structure was 
solved with 2 molecules in the ASU and a solvent content of 49.8 %. 
4.3.2. Discussion of substrate-bound Y404F dm2 structure 
Each molecule contained residues 7-457 and a total of 847 waters were modelled in the ASU. The final 
model was refined to give R and Rfree values of 0.1667 and 0.2023, respectively, to a resolution of 1.80 
Å. The full statistics can be seen in Appendix 7.1.3. The overall structure of the molecule is very similar 
to dm2. Once again the movement in the C-terminus is seen, as shown in Figure 4.15. In this structure 
however there is very little movement in residues 240-290. This contradicts the theory that the two 
sections are connected, or at least that the connection is particularly strong. Given this lack of movement 




Figure 4.15 Crystal structure of substrate-bound Y404F, showing both molecules overlaid with one another. 
Molecule A is coloured in cyan, molecule B is coloured violet. L-Kyn is coloured orange. RMSD = 0.995 Å from 
445 aligned Cα atoms. 
Molecule Mean B-factor of C-terminus/Mean B-factor of structure 
Closed 1.3 
Open 1.3 
Table 4.8 Average B-factor for residues 370-400 of substrate-bound Y404F divided by average B-factor of overall 
structure. 
The B-factors shown in Table 4.8 show the same value for the closed molecule and the open molecule. 
This goes against the previous findings. While many datasets for the Y404F protein matched the pattern 
of the closed molecule showing lower B-factors they did not show the same level of L-Kyn occupancy. 
Therefore this model was selected. The B-factors shown in Table 4.8 are also closer than any other 
structure, meaning the two molecules are very similar in mobility. 
As shown in Figure 4.16 the positioning of F404 is very similar to that of Y404 in dm2. The similarity 
between the two amino acids makes it difficult to ensure presence of a phenylalanine residue over a 
tyrosine. When a tyrosine residue is used in the model however the Fo-Fc map clearly shows the 




Figure 4.16 a. Crystal structure of substrate-bound Y404F, modelled with Tyr as residue 404. Fo-Fc map is 
shown in red (contoured as -0.32 eÅ-3, 3.25 σ). b. Crystal structure of substrate-bound Y404F overlay with dm2 
showing residues 404. Y404F coloured cyan, dm2 coloured green. RMSD = 0.419 Å from 446 aligned Cα atoms. 
Only the absence of the hydroxyl affects a change on the binding of the substrate. Once again the 
occupancy of L-Kyn is much lower than seen in dm2. In order to model L-Kyn the contouring of 
electron density was decreased, as shown in Figure 4.17. This is discussed further in section 4.4.2. 
 
Figure 4.17 Crystal structure of substrate-bound Y404F, showing L-Kyn. 2Fo-Fc map shown in blue (contoured 




Figure 4.18 a. Crystal structure of active site of Y404F bound with L-Kyn, molecule A. b. Chemdraw schematic of 
Y404F bound with L-Kyn. Distances between atoms are in Å and shown as red dashed lines. The site of 
oxidation is denoted with an asterisk (*). 
As seen in Figure 4.18, L-Kyn shows similar positioning to that seen in dm2. The acid group positioning 
implies a direct H-bond to Y98, unlike in dm2. The acid remains close enough to R84 to form an 
electrostatic interaction, as exhibited in dm2. The distance from the acid to N369 is now too large to 
form any meaningful interaction. As a result of the substitution the amine has not only lost the Y404 
interaction but also the H320 interaction it showed in dm2. This could allow for the slight movement 
of L-Kyn resulting in this new distribution of binding interactions. Despite this the overall positioning 
of L-Kyn is still close enough to allow interaction between it and the FAD.  This means catalysis can 
still occur, unlike in R84K. Where dm2 exhibited 6 meaningful interactions between substrate and 
binding site Y404F only shows 3. This bonding form is clearly less effective than that seen in dm2, as 
shown by the large increase in KM for Y404F. 
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4.4. Substrate-free Y404F dm2 
4.4.1. Crystal growth and data collection 
Using the protein prepared in section 4.3 new crystal trays were prepared using the same method as 
described in section 4.3.1 with no exposure to L-Kyn. These substrate-free crystals were sent to 
Diamond Light Source. Using beamline i03 data were collected. 
 
Figure 4.19 Mounted crystal of substrate-free Y404F used for data collection. 
From the crystal shown in Figure 4.19 1500 images were collected with beamline transmission 100 %, 
exposure of 0.1 s and oscillation of 0.15°. The statistics shown in Table 4.9 were calculated using the 
programs iMosflm and Scala159, 160. 
Resolution 
(Å) 
Rmerge Mean (I)/σ(I) Completeness 
(%) 
Multiplicity 
67.90-1.65 0.070 8.7 99.8 3.7 
Table 4.9 Data collection statistics for a substrate-free Y404F crystal. All calculated from overall data, for full data 
collection statistics see Appendix 7.1.3. 
Refinement and model editing were performed as for dm2, described in section 2.8. The structure was 
solved with 2 molecules in the ASU and a solvent content of 48.7 %. 
4.4.2. Discussion of substrate-free Y404F dm2 structure 
Each molecule contained residues 6-459 and a total of 605 waters were modelled in the ASU. The final 
model was refined to give R and Rfree values of 0.1748 and 0.2099, respectively, to a resolution of 1.65 
Å. The full statistics can be seen in Appendix 7.1.3. The movement in the C-terminus was also exhibited 
between the two molecules within the ASU, as shown in Figure 4.20. Once again there is no movement 
observed in residues 240-290, implying no strong relationship between these residues and the C-
87 
 
terminus exists. The possibility that residue Y404 is important to this movement is very remote; given 
Y404 is positioned very far from residues 240-290. 
 
Figure 4.20 Crystal structure of substrate-free Y404F, showing both molecules overlaid with one another. 
Molecule A is coloured in orange, molecule B is coloured green. RMSD = 0.732 Å from 456 aligned Cα atoms. 
Molecule Mean B-factor of C-terminus/Mean B-factor of structure 
Closed 1.4 
Open 1.8 
Table 4.10 Average B-factor for residues 370-400 of substrate-free Y404F divided by average B-factor of overall 
structure. 
The B-factors, shown in Table 4.10, return to the expected relationship of the closed molecule having 
a lower value. The expected movement in C-terminus is also observed between the two molecules. This, 
however, was not the case in all the substrate free Y404F crystals. Much like the substrate free R84K 
crystals, some were capable of being solved with only one molecule within the ASU. Meaning the 
movement of C-terminus was small enough to assign to two molecules as crystallographically identical. 
The positioning of F404 is very similar between the two substrate-free molecules, as well as to the 




Figure 4.21 Crystal structure of Y404F molecules, showing residue F404 from both molecules of 
substrate-bound and substrate-free structures. RMSD values were generated by aligning each molecule to the 
“closed” substrate-bound molecule (cyan). RMSD values of the overlays range from 0.578 – 1.037 Å, from at 
least 445 aligned Cα atoms in each case. 
This shows that, despite the unexpected behaviour in terms of the C-terminus, the F404 residue is totally 
unaffected by presence or absence of L-Kyn. 
Much like R84K the Fo-Fc maps of the substrate-exposed and substrate-free structures were compared. 
Firstly the substrate and any water molecules were removed from the models, these were then refined 
using Refmac5164. The results are shown in Figure 4.22. 
 
Figure 4.22 Crystal structures of Y404F showing the active site. a. Substrate-exposed Y404F with Fo-Fc map 
(contoured at 0.29 eÅ-3, 2.95 σ). b. Substrate-free Y404F with Fo-Fc map (contoured at 0.31 eÅ-3, 2.96 σ). 
There are once again differences between the substrate-exposed and substrate-free Fo-Fc maps. These 
are not quite as marked as in the R84K structures because of the green peak next to Y98 in both 
structures. An absence of electron density correlating to acetate or glycerol in the substrate-free 
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molecule reduces the likelihood that these molecules correspond to electron density in the 
substrate-bound structure. In Figure 4.22 b. the peak is spherical and can be attributed to the water 
molecule seen in the dm2 structures in Figure 3.14 and Figure 3.23, rather than acetate or glycerol. The 
occupancy of L-Kyn is so low in the substrate-exposed Y404F; many molecules within the crystal will 
only have this water molecule present, while others will have L-Kyn bound. This makes the modelling 
of L-Kyn more difficult. However, one can still see differences between these two peaks. There are also 
more peaks in the Fo-Fc map of the substrate-exposed model. This supports the case for L-Kyn presence, 
albeit at low occupancy. 
The use of polder maps was again implemented to assess the presence of L-Kyn. The substrate molecule 
was selected for omission; a polder map was then created using Phenix170, 171. The three maps were then 
compared using correlation coefficients; see section 2.8.2 for details. 
Maps being compared Local correlation coefficient Peak correlation coefficient 
1, 2 0.66 0.73 
1, 3 0.83 0.80 
2, 3 0.55 0.58 
Table 4.11 Correlation coefficients of polder map calculations for substrate-bound Y404F. 
Given the correlation is greatest between maps 1 and 3 the polder map supports the presence of L-Kyn. 
Maps 1 and 3 also show the higher peak correlation coefficient, increasing the likelihood of substrate 
presence. Compared to R84K these findings are more definitive. When used in consideration of the 
other supporting factors, such as the Fo-Fc maps and the high ligand occupancy, the data more strongly 
reinforce the argument for the presence of a weakly bound substrate. 
This section has shown the importance of the interaction between Y404 and L-Kyn. When this 
interaction breaks down the binding ability of the protein is affected, as exhibited in the kinetic and 
structural data, with reduced binding interactions leading to a higher KM and lower kcat. 
4.5. Substrate-bound H320F dm2 
4.5.1. Crystal growth and data collection 
H320F dm2 protein was expressed and purified as described in Chapter 2 using the plasmid created by 
H. Bell156. The protein was concentrated to a concentration of 1.0 mM, confirmed by UV-Vis 




Figure 4.23 UV-visible spectrum of 1:100 dilution of H320F. Concentration calculated from absorbance of 0.125 
at 450 nm with ε450 of 12,300 M-1 cm-1. 
The new PEG 8K conditions were used to set up hanging drop trays as described in Chapter 2. Two 
trays were set up, one co-crystallised with 1 mM L-Kyn, the other without L-Kyn. Crystals formed 
within 24 hours. Selected crystals were then soaked in 1 μL drops comprising of mother liquor stabilised 
with extra PEG 8K and 1 mM L-Kyn. After a further 24 hours individual crystals were flash cooled in 
liquid N2 and sent to the Diamond light source.  
Using beamline i03 data were collected. All crystals exhibited P1211 spacegroup with dimensions 
similar to those seen in Table 3.4. 
 
Figure 4.24 Mounted crystal of substrate-exposed H320F used for data collection. 
From the crystal shown in Figure 4.24 2400 images were collected with beamline transmission 20 %, 
exposure of 0.1 s and oscillation of 0.15°. The statistics shown in Table 4.12 were calculated using the 




















Rmerge Mean (I)/σ(I) Completeness 
(%) 
Multiplicity 
34.54-1.89 0.049 21.3 99.8 6.0 
Table 4.12 Data collection statistics for a substrate-exposed H320F crystal. All calculated from overall data, for 
full data collection statistics see Appendix 7.1.4. 
Refinement and model editing were performed as for dm2, described in section 2.8. The structure was 
solved with 2 molecules in the ASU and a solvent content of 47.2 %. 
4.5.2. Discussion of substrate-bound H320F dm2 structure 
Each molecule contained residues 6-457 and a total of 733 waters were modelled in the ASU. The final 
model was refined to give R and Rfree values of 0.1550 and 0.2005, respectively, to a resolution of 
1.89 Å. The full statistics can be seen in Appendix 7.1.4. The movement in the C-terminus was also 
exhibited between the two molecules within the ASU, as shown in Figure 4.25. 
 
Figure 4.25 Crystal structure of substrate-bound H320F showing both molecules overlaid with one another. 




Molecule Mean B-factor of C-terminus/Mean B-factor of structure 
Closed 1.1 
Open 1.9 
Table 4.13 Average B-factor for residues 370-400 of substrate-bound H320F divided by average B-factor of 
overall structure. 
The C-terminus shift is shown in Figure 4.25 is similar to that seen in dm2, as is the movement of 
residues 240-290. The B-factors shown in Table 4.13 also exhibit the same pattern of the closed 
molecule having the lower B-factors in the C-terminus. 
The positioning of F320 is very similar to that of H320 in dm2 (the rings are superposable). The 
similarity between the two residues makes it difficult to ensure presence of a phenylalanine rather than 
a histidine. When using both 2Fo-Fc and Fo-Fc maps the results are not definitive, as shown in Figure 
4.26.  
 
Figure 4.26 a. Crystal structure of substrate-bound H320F overlay with dm2 showing residues 320. 2Fo-Fc map 
is shown in blue (contoured at 0.50 eÅ-3, 1.5 σ). H320F coloured cyan, dm2 coloured green. b. Crystal structure 
of substrate-bound H320F, modelled with His as residue 320. Fo-Fc map is shown in red (contoured at -0.28eÅ-3, 
2.7 σ). 
Despite the presence of a phenylalanine codon being confirmed by Sanger sequencing for the H320F 
gene the protein was tested using mass spectrometry to support the presence of the correct residue. 
H320F protein prepared in section 4.5 and dm2 protein prepared in section 3.2.2 were analysed using 
liquid chromatography-mass spectrometry. 15 μL of each protein was loaded onto an Aeris Widepore 
3.6 μm C4 50 x 2.1 mm column connected to a Waters ZSpray Lockspray electrospray ionisation source, 





Figure 4.27 Spectra of H320F and dm2 using liquid chromatography electrospray ionisation mass spectrometry. 
The mass of H320F is expected to be 10 Daltons greater than dm2. The mass of H320F was calculated 
to be 50564.3±1.5 Da while dm2 was calculated to be 50556.1±0.6 Da. This shows the appropriate mass 
difference between the two, confirming the substitution mutation of H320 to a phenylalanine. 
The occupancy of L-Kyn is higher in H320F than in either R84K or Y404F, which matches their relative 
KM values. The level of electron density surrounding L-Kyn is therefore greater, if not to quite the same 
extent as dm2, as shown in Figure 4.28. This is in line with H320F exhibiting a very similar binding 
affinity to dm2. 
 
Figure 4.28 Crystal structure of crystal bound H320F showing L-Kyn and 2Fo-Fc map shown in blue (contoured 
at 0.43 eÅ-3, 1.51 σ). 
When comparing the active sites of H320F to dm2 there is very little difference, as shown in Figure 
4.29. The same interactions are seen between substrate and active site due to the almost identical 
positioning of the key residues and L-Kyn. As with dm2 the presence of L-Kyn is restricted to only one 




Figure 4.29 Crystal structure of substrate-bound H320F overlaid with substrate-bound dm2, showing L-Kyn and 
binding residues. H320F is coloured cyan, dm2 is coloured green. RMSD = 0.393 Å from 435 aligned Cα atoms. 
There is very little change between H320F and dm2 in terms of H-bonding involving residue 320. This 
is because only the carbonyl of residue 320 interacts with the substrate. There are two water molecules 
that are within H-bonding distance from the nitrogen atoms of H320, but both of these form other 
interactions with surrounding groups including the carbonyl of residue 320, T408 and R403. Therefore 
we do not see a difference in the positioning of these waters in H230F. 
4.6. Substrate-free H320F dm2 
4.6.1. Crystal growth and data collection 
Using the protein prepared in section 4.5 new crystal trays were prepared using the same method as 
described in section 4.5.1, with no exposure to L-Kyn. After 48 hours these substrate-free crystals were 




Figure 4.30 Mounted crystal of substrate-free H320F used for data collection. 
From the crystal shown in Figure 4.30 1800 images were collected with beamline transmission 20 %, 
exposure of 0.15 s and oscillation of 0.15°. The statistics shown in Table 4.14 were calculated using the 
programs iMosflm and Scala159, 160. 
Resolution 
(Å) 
Rmerge Mean (I)/σ(I) Completeness 
(%) 
Multiplicity 
34.72-1.90 0.079 9.1 99.7 4.3 
Table 4.14 Data collection statistics for a substrate-free H320F crystal. All calculated from overall data, for full 
data collection statistics see Appendix 7.1.4. 
Refinement and model editing were performed as for dm2, described in section 2.8. The structure was 
solved with 2 molecules in the ASU and a solvent content of 47.6 %. 
4.6.2. Discussion of substrate-free H320F dm2 structure 
Each molecule contained residues 6-457 and a total of 465 waters were modelled in the ASU. The final 
model was refined to give R and Rfree values of 0.1796 and 0.2272, respectively, to a resolution of 
1.90 Å. The full statistics can be seen in Appendix 7.1.4. The movements in the C-terminus and residues 




Figure 4.31 Crystal structure of substrate-free H320F showing both molecules overlaid with one another. 
Molecule A is coloured in orange, molecule B is coloured green. RMSD = 0.926 Å from 477 aligned Cα atoms. 
Molecule Mean B-factor of C-terminus/Mean B-factor of structure 
Closed 1.7 
Open 2.0 
Table 4.15 Average B-factor for residues 370-400 of substrate-free H320F divided by average B-factor of overall 
structure. 
The C-terminus shift observed in the substrate-free form of H320F is similar to that seen in dm2. The 
relation of B-factors between the two molecules are also as expected, as shown in Table 4.15, with the 
closed molecule having the lower value. The positioning of H320 is very similar between the two 
substrate-free molecules, as well as the substrate-bound model. This shows that the presence of substrate 
does not have an effect upon the positioning of this residue, which is consistent with it having no major 




Figure 4.32 Crystal structure of H320F molecules, showing residue F320 from both molecules of 
substrate-bound and substrate-free structures. RMSD values were generated by aligning each molecule to the 
“closed” substrate-bound molecule (cyan). RMSD values of the overlays range from 0.351 – 1.255 Å, from at 
least 436 aligned Cα atoms in each case. 
The active sites in the substrate-free and substrate-bound H320F molecules are also very similar, as 
shown in Figure 4.33. 
 
Figure 4.33 Crystal structure of substrate-free H320F (orange) overlaid with substrate-bound H320F (cyan), 
showing L-Kyn and binding residues. RMSD = 0.351 Å from 441 aligned Cα atoms. 
H320F behaves very similarly to dm2 with very little difference seen in the active site regardless of the 
absence or presence of substrate. 
As noted in this section there is great similarity in substrate binding, C-terminus movement and enzyme 
kinetics between dm2 and H320F. H320F has an analogous active site to hKMO and this similarity is 




This chapter has examined the structural rationalisations for observations made in Michaelis-Menten 
kinetics in mutant forms of dm2. The influence of altering certain interactions within the active site 
vary between inconsequential to inactivating. The behaviour of substrate and residues within the active 
site provided reasoning for the Michaelis-Menten profile of R84K and Y404F, re-asserting the 
importance of these residues in substrate binding. The use of dm2 as a model for hKMO is also endorsed 
by the similarity demonstrated between dm2 and H320F. 
The data surrounding the C-terminus are less straightforward. The structures within this chapter go 
against expectations; these being one closed conformation molecule with lower B-factors and one open 
molecule with higher B-factors. Firstly the molecules within the substrate free R84K structure are very 
similar, so similar that in some crystals they were considered symmetrical. This was also seen in some 
substrate free Y404F crystals. Secondly in substrate bound Y404F the B-factors of the closed molecule 
are shown to be slightly higher than the open molecule. This also contradicts the argument that the 
closed C-terminus is stabilised by L-Kyn. 
From the data shown in substrate-free R84K it could be argued that the presence of substrate is possibly 
required to stabilise the C-terminus in the closed conformation. This is refuted by the presence of a 
closed molecule, with lower C-terminus B-factors in the structures of substrate free dm2, H320F and 
Y404F. 
The movements of residues 240-290 are also atypical in this chapter. They behave as expected in most 
structures, even showing reduced movement to correlate with the reduced C-terminus movement in 
substrate-free R84K. This reduced movement, however, continues in structures where movement would 
be expected, in substrate-exposed and substrate-free Y404F. This makes a clear conclusion regarding 
the link between the two sections difficult to propose. 
In general a pattern for the behaviour of the C-terminus is difficult to determine. Unlike in previous 
models the data presented in these latest chapters show there is not a clear relationship between L-Kyn 
presence and the stabilisation of one C-terminal conformation. The next chapter focuses upon the 




Chapter 5:  C-terminus residues 
5.1. Introduction 
In previous work by Martin Wilkinson of this group a network of interactions was proposed to be 
important for the stabilisation of the closed conformer of dm2143. This network was formed between 
residues in both the C-terminal domain and the remainder of the protein. These residues appeared to 
interact, closing a channel in the protein and excluding solvent from the active site to allow catalysis. It 
was also hypothesised that the presence of L-Kyn in the active site affected these residues causing this 
channel to close. In previous chapters it has been shown that the presence of L-Kyn has less effect upon 
the movement of the C-terminus than previously thought. This chapter investigates how the disruption 
of this potential network affects the movement of the C-terminus and the mechanism of dm2. 
As seen in chapter 1, the residues identified as important to the putative network were R84, P97, E372, 
Y382 and R386. Substitution mutations were introduced, by Wilkinson, which targeted the residues 
R386 and E372, as these were seen to act as bridges between the two domains143. The effect of the 
substitutions R386K and E372T on the kinetic profile of the protein can be seen in Table 5.1. 
Protein KM (μM) kcat (s-1) kcat/KM (s-1 μM-1) 
dm2 8.8 ± 1.5 8.9 ± 1.1 1.01 
E372T dm2* 10.3 ± 0.7 8.7 ± 0.1 0.84 
R386K dm2 17.0 ± 1.4 12.0 ± 0.9 0.71 
Table 5.1 Summary of Michaelis-Menten kinetic data for mutant forms of dm2143. *E372T mutant also contained 
a L367R mutation. 
There are no major differences between dm2, R386K and E372T in terms of Michaelis-Menten kinetics. 
This suggests that the residues in question are not directly involved in binding and that any disruption 
to the interactive network has little effect upon the efficiency of the enzyme. 
In previous work the movement of the C-terminus in these mutants was also studied and it was found 
that the domain took up a mixed conformation, neither open nor closed143. These measurements were, 
however, hampered by the differing space groups of substrate-bound and substrate-free structures. 
Using the new PEG 8K crystallising conditions this issue is overcome. The previous two chapters have 
shown that the presence of L-Kyn is not necessary for dm2 to take up a closed conformation. This 
chapter investigates the presence of the putative inter-domain binding network and its effect upon the 
C-terminus. 
This chapter will also present data of surface calculations for the PfKMO variants analysed throughout 
this thesis. The measurement of the void volume or surface area of the active site of PfKMO could 
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provide a more quantitative analysis of the role of the C-terminus when comparing the open and closed 
conformers. 
5.2. Substrate-exposed R386K dm2 
5.2.1. Crystal growth and data collection 
R386K protein was expressed and purified as described in Chapter 2 using the plasmid created by 
Martin Wilkinson143. The protein was concentrated by centrifugation to a concentration of 430 μM 
confirmed by UV-Vis spectrophotometry, as shown in Figure 5.1. 
 
Figure 5.1 UV-Visible spectrum of 1:50 dilution of R386K. Concentration calculated from absorbance of 0.107 at 
450 nm with ε450 of 12,300 M-1 cm-1. 
The new PEG 8K conditions were used to set up hanging drop trays as described in Chapter 2. Two 
trays were set up, one co-crystallised with 1 mM L-Kyn, the other without L-Kyn. Within 24 hours a 
number of large crystals had formed. Selected crystals were then soaked in 1 μL drops comprising of 
mother liquor stabilised with extra PEG 8K and 1mM L-Kyn. Crystals were then left for a further 24 
hours and in some cases more than 72 hours. Individual crystals were flash cooled in liquid N2 and sent 
to the Diamond light source. Data were collected using beamline i03. All crystals exhibited P1211 


















Figure 5.2 Mounted crystal of substrate exposed R386K used for data collection. 
From the crystal shown in Figure 5.2 1300 images were collected with beamline transmission 
20.00 %, exposure of 0.1 s and oscillation of 0.15°. The statistics shown in Table 5.2 were calculated 
using the program Xia2 and Scala 160, 161. 
Resolution (Å) Rmerge Mean (I)/σ(I) Completeness 
(%) 
Multiplicity 
29.02-1.65 0.054 11.3 99.5 3.3 
Table 5.2 Data collection statistics of a substrate-exposed R386K crystal. All calculated from overall data, for full 
data statistics see Appendix 7.1.5. 
Refinement and model editing were performed as for dm2, described in section 2.8. The structure was 
solved with 2 molecules in the ASU and a solvent content of 47.7%. An overall image of the two 





Figure 5.3 Crystal structure of substrate-exposed R386K showing both molecules in the ASU. Molecule A is 
coloured cyan, molecule B is coloured violet. 
5.2.2. Discussion of substrate-exposed R386K dm2 structure 
Each molecule contained residues 6-457 and a total of 572 waters were modelled in the ASU. The final 
model was refined to give R and Rfree values of 0.1720 and 0.2095, respectively, to a resolution of 
1.65 Å. The full statistics can be seen in Appendix 7.1.5. The movement in the C-terminus was also 





Figure 5.4 Crystal structure of substrate exposed R386K, showing both molecules overlaid with one another. 
Molecule A is coloured cyan, molecule B is coloured violet. RMSD = 0.964 Å from 442 aligned Cα atoms. 
Molecule Mean B-factor of C-terminus/Mean B-factor of structure 
Closed 1.4 
Open 1.7 
Table 5.3 Average B-factor for residues 370-400 of substrate exposed R386K divided by average B-factor of 
overall structure. 
As seen in previous dm2 and dm2 mutant structures the movements of the C-terminus and residues 240-
290 are present. The C-terminus B-factors, shown in Table 5.3, are also as expected with the closed 
molecule showing a lower value. The major difference between R386K and the enzymes of previous 
chapters is that L-Kyn is absent from the active site. This was found for all structures solved despite 
both co-crystallisation and crystal soaking being employed in addition to a much longer soaking time. 
Fo-Fc maps of substrate-exposed and substrate-free structures were compared, much like R84K and 
Y404F. Ligand and water molecules were removed from the active site and the models were refined 




Figure 5.5 Crystal structures of R386K showing the active site. a. Substrate-exposed R386K with Fo-Fc map 
(contoured at 0.36 eÅ-3, 2.97 σ) b. Substrate-free R386K with Fo-Fc map (contoured at 0.30 eÅ-3, 2.96 σ). 
Most of the green blobs exhibited in substrate-exposed R386K are also present in substrate-free R386K, 
including those in the expected position of L-Kyn. These peaks in the Fo-Fc maps model well as water 
molecules. These factors and the minimal differences between the two Fo-Fc maps suggest no L-Kyn 
occupancy in the substrate exposed structure. 
Despite this the positioning of residues within the active site itself appears unaffected by the R386K 
mutation. A comparison with dm2 can be seen in Figure 5.6. 
 
Figure 5.6 Crystal structures of substrate exposed R386K and substrate-bound dm2 overlaid, showing the active 




The lack of L-Kyn occupancy is difficult to explain, given R386K has a much lower KM than Y404F 
for example. Even with the substitution of such an important residue evidence of L-Kyn occupancy is 
still observed in Y404F structures. This may suggest that the role of the C-terminus includes binding of 
substrate; though this is very difficult to argue with this evidence alone. 
Due to the high B-factors within the surrounding domain it was necessary to increase the contouring of 
the 2Fo-Fc map to 1.0 σ in order to visualise the electron density of residue K386. This can be seen in 
Figure 5.7. 
 
Figure 5.7 Crystal structures of substrate-exposed R386K and substrate-bound dm2 overlaid, showing residue 
386. R386K is shown in cyan, dm2 is shown in green, 2Fo-Fc map is shown in blue (contoured at 0.36 eÅ-3, 
1.00 σ). RMSD = 1.537 Å from 437 aligned Cα atoms. 
K386 is in a similar position to R386 of dm2, however the RMSD of the alignment is much higher than 
previous models. The distances between the two Cα atoms of residues 386 is 2 Å and the RMSD is 
1.5 Å, making comparisons between the two models more difficult. Figure 5.4, however, shows a much 
smaller RMSD of 0.483 Å between the two R386K molecules, which are still distinguishable as open 
and closed. This suggests that the disruption of the putative network has no effect upon the ability of 
the protein to take up a closed conformation. 
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5.3. Substrate-free R386K dm2 
5.3.1. Crystal growth and data collection 
R386K crystals with no exposure to L-Kyn, prepared in section 5.2, were analysed at the same time as 
substrate-exposed crystals. Using beamline i03 data were collected. 
 
Figure 5.8 Mounted crystal of substrate free R386K used for data collection. 
From the crystal shown in Figure 5.8 1900 images were collected with beamline transmission 20.00 %, 
exposure of 0.1 s and oscillation of 0.10°. The statistics shown in Table 5.4 were calculated using the 
programs iMosflm and Scala159, 160. 
Resolution (Å) Rmerge Mean (I)/σ(I) Completeness 
(%) 
Multiplicity 
68.19-1.89 0.066 8.9 99.4 2.9 
Table 5.4 Data collection statistics of a substrate-free R386K crystal. All calculated from overall data, for full data 
statistics see Appendix 7.1.5. 
Refinement and model editing were performed as for dm2, described in section 2.8. The structure was 
solved with 2 molecules in the ASU and a solvent content of 48.5%. 
5.3.2. Discussion of substrate-free R386K dm2 structure 
Each molecule contained residues 6-457 and a total of 410 waters were modelled in the ASU. The final 
model was refined to give R and Rfree values of 0.1770 and 0.2240, respectively, to a resolution of 
1.89 Å. The full statistics can be seen in Appendix 7.1.5. The movements in the C-terminus and residues 




Figure 5.9 Crystal structure of substrate-free R386K, showing both molecules overlaid with one another. 
Molecule A is coloured green, molecule B is coloured orange. RMSD = 0.877 Å from 446 aligned Cα atoms. 
Molecule Mean B-factor of C-terminus/Mean B-factor of structure 
Closed 1.6 
Open 1.9 
Table 5.5 Average B-factor for residues 370-400 of substrate-free R386K divided by average B-factor of overall 
structure. 
The substrate-free R386K follows suit in exhibiting an open and closed conformer and having lower 





Figure 5.10 Crystal structures of substrate-free R386K and substrate-bound dm2 overlaid, showing residue 386. 
R386K is shown in orange, dm2 is shown in green, 2Fo-Fc map is shown in blue (contoured at 0.30 eÅ-3, 1.00 σ). 
RMSD = 0.618 Å from 444 aligned Cα atoms. 
In previous work it was postulated that the movement of the C-terminus of dm2 was controlled by the 
presence of L-Kyn, and this was enacted through a network of interactions. The data presented here 
appear to counter both of these hypotheses. Substrate-free R386K is capable of taking up the same 
closed conformation as the substrate-bound dm2 despite disruption of the putative interactive network, 





Figure 5.11 Crystal structure showing residues involved in the putative interacting network of the C-terminus of 
R386K a. Closed molecule of L-Kyn-exposed R386K b. Open molecule of L-Kyn-exposed R386K c. Closed 
molecule of L-Kyn-free R386K d. Open molecule of L-Kyn-free R386K. 2Fo-Fc maps are shown in blue (L-Kyn 
exposed molecules contoured at 0.36 eÅ-3, 1.0 σ, L-Kyn free molecules contoured at 0.30 eÅ-3, 1.0 σ). Distances 
between atoms are in Å and shown as red dashed lines. 
Figure 5.11 shows the positioning of the other residues within the putative interactive network in all the 
R386K molecules. The overall positioning of K386 is similar to R386 seen in dm2. However, much 
like its counterpart in dm2 the residue is very mobile. The lysine appears to be a comparable distance 
from P97 as R386 is in dm2 in the closed molecule. However, given the mobility and relatively 
inconsistent positioning of R386 in dm2 it is unsurprising K386 follows a similar trend.  The mobility 
of the residue therefore leads to very sparse density shown in the 2Fo-Fc map. Consequently 
comparisons between the two residues are difficult to make. The conclusions we can form are twofold. 
Firstly the distances measured between the residues are similar to dm2 in that they are too large to form 
any meaningful interactions. Secondly the appearance of closed or open conformations seems 
unaffected by this mutation, as is the kinetic ability of the protein.  
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5.4. Substrate-exposed E372T dm2 
5.4.1. Crystal growth and data collection 
The extra L367R mutation present in the kinetic testing of E372T in Table 5.1 was corrected for 
crystallography. E327T protein was expressed and purified as described in Chapter 2 using the plasmid 
created by Martin Wilkinson143. The protein was concentrated by centrifugation to a concentration of 
585 μM confirmed by UV-Vis spectrophotometry, as shown in Figure 5.12. 
 
Figure 5.12 UV-Visible spectrum of 1:50 dilution of E372T. Concentration calculated from absorbance of 0.144 at 
450 nm with ε450 of 12,300 M-1 cm-1. 
The new PEG 8K conditions were used to set up hanging drop trays as described in Chapter 2. Two 
trays were set up, one co-crystallised with 1 mM L-Kyn, the other without L-Kyn. After 24 hours only 
one crystal had formed from both the trays. Two more trays were prepared, one with 1 mM L-Kyn, one 
without L-Kyn. The crystal was crushed and used to seed the drops of the new trays, using the method 
described in Chapter 2. Crystals formed after 24 hours. Several dilutions of the seeding solution were 
used with the 1:1000 dilution yielding the largest and highest diffracting crystals. Selected crystals were 
then soaked in 1 μL drops comprising of mother liquor stabilised with extra PEG 8K and 1 mM L-Kyn. 
Crystals were then left for a further 24 hours and in some cases more than 72 hours. Individual crystals 




















Figure 5.13 Mounted crystal of substrate-exposed E372T used for data collection. 
From the crystal shown in Figure 5.13 3600 images were collected with beamline transmission 20.00 %, 
exposure of 0.1 s and oscillation of 0.05°. The statistics shown in Table 5.6 were calculated using the 
programs iMosflm and Scala159, 160. 
Resolution (Å) Rmerge Mean (I)/σ(I) Completeness 
(%) 
Multiplicity 
67.69-1.79 0.047 11.0 99.5 3.1 
Table 5.6 Data collection statistics of a substrate-exposed E372T crystal. All calculated from overall data, for full 
data statistics see Appendix 7.1.6. 
Refinement and model editing were performed as for dm2, described in section 2.8. The structure was 
solved with 2 molecules in the ASU and a solvent content of 47.4%. 
 
5.4.2. Discussion of substrate-exposed E372T dm2 structure 
The model contained residues 6-459 in molecule A, 6-457 in molecule B and 356 waters in the ASU. 
The final model was refined to give R and Rfree values of 0.1859 and 0.2297, respectively, to a resolution 
of 1.79 Å. The full statistics can be seen in Appendix 7.1.6. The movement of the C-terminus was 
exhibited between the two molecules within the ASU, as shown in Figure 5.14. Table 5.7 describes the 
average B-factors for the C-termini. The movement of residues 240-290 is also seen but is significantly 
decreased, unlike the shift in the C-terminus. This supports the idea that the movement is not caused by 




Figure 5.14 Crystal structure of substrate-exposed E372T, showing both molecules overlaid with one another. 
Molecule A is coloured cyan, molecule B is coloured violet. RMSD = 0.827 Å from 448 aligned Cα atoms. 
Molecule Mean B-factor of C-terminus/Mean B-factor of structure 
Closed 1.6 
Open 1.9 
Table 5.7 Average B-factor for residues 370-400 of substrate-exposed E372T divided by average B-factor of 
overall structure. 
Both the movement of the C-terminus and the lower B-factor in the closed molecule are present within 
the model. As with R386K L-Kyn is undetected in the active site, despite extended soaking time. 
Comparisons of the Fo-Fc maps of substrate-exposed and substrate-free E372T structures are shown in 




Figure 5.15 Crystal structures of E372T showing the active site. a. Substrate-exposed E372T with Fo-Fc map 
(contoured at 0.27 eÅ-3, 2.99 σ) b. Substrate-free E372T with Fo-Fc map (contoured at 0.28 eÅ-3, 3.00 σ). 
As with R386K the positioning of active site residues is very similar to dm2, as shown in Figure 5.16.  
 
Figure 5.16 Crystal structures of substrate-exposed E372T and substrate-bound dm2 overlaid, showing the 
active site. E372T is shown in cyan, dm2 is shown in green. RMSD = 0.582 Å from 435 aligned Cα atoms. 
The B-factors of the molecule overall are very high and the difficulty in crystallising the protein may 
indicate a less static, more dynamic protein, particularly in the C-terminus. This is difficult to quantify, 





Figure 5.17 Crystal structures of substrate-exposed E372T and substrate-bound dm2 overlaid, showing residue 
372. E372T is shown in cyan, dm2 is shown in green, 2Fo-Fc map is shown in blue (contoured at 0.26 eÅ-3, 
1.00 σ). RMSD = 0.582 Å from 435 aligned Cα atoms. 
As shown in Figure 5.17, the positioning of the threonine and direction of the alcohol group are very 
different to the acid group of the glutamate. This means any potential interactivity E372 might have 
been involved with would be greatly diminished if not impossible with the threonine side chain. As 
shown in Figure 5.14 the molecule is still capable of forming a closed conformation. 
5.5. Substrate-free E372T dm2 
5.5.1. Crystal growth and data collection 
E372T crystals with no exposure to L-Kyn, prepared in section 5.4, were analysed at the same time as 
substrate-bound crystals. Using beamline i02 data were collected. 
 
Figure 5.18 Mounted crystal of substrate-free E372T used for data collection. 
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From the crystal shown in Figure 5.18 2000 images were collected with beamline transmission 20.00 %, 
exposure of 0.05 s and oscillation of 0.10°. The statistics shown in Table 5.8 were calculated using the 
programs iMosflm and Scala159, 160. 
Resolution (Å) Rmerge Mean (I)/σ(I) Completeness 
(%) 
Multiplicity 
67.30-1.88 0.085 6.3 99.1 3.4 
Table 5.8 Data collection statistics of a substrate-free E372T crystal. All calculated from overall data, for full data 
statistics see Appendix 7.1.6. 
Refinement and model editing were performed as for dm2, described in section 2.8. The structure was 
solved with 2 molecules in the ASU and a solvent content of 46.5%. 
5.5.2. Discussion of substrate-free E372T dm2 structure 
Each molecule contained residues 6-457 and a total of 314 waters were modelled in the ASU. The final 
model was refined to give R and Rfree values of 0.1973 and 0.2435, respectively, to a resolution of 
1.88 Å. The full statistics can be seen in Appendix 7.1.6. The movement in the C-terminus was also 
exhibited between the two molecules within the ASU, as shown in Figure 5.19. The movement of 
residues 240-290 is also observed but, as seen in section 5.4.2, is significantly less than expected when 





Figure 5.19 Crystal structure of substrate-free E372T, showing both molecules overlaid with one another. 
Molecule A is coloured green, molecule B is coloured orange. RMSD = 0.888 Å from 452 aligned Cα atoms. 
Molecule Mean B-factor of C-terminus/Mean B-factor of structure 
Closed 1.6 
Open 1.8 
Table 5.9 Average B-factor for residues 370-400 of substrate-free E372T divided by average B-factor of overall 
structure. 
As shown in Figure 5.19 and Table 5.9 the model exhibits the C-terminus movement and lower 
B-factors in the closed conformation. In agreement with findings of the R386K molecule the disruption 
of any potential interactive network between the C-terminus and the rest of the protein has no effect on 




Figure 5.20 Crystal structure of E372T molecules, showing residue T372 from both molecules of substrate-
exposed and substrate-free structures. RMSD values were generated by aligning each molecule to the “closed” 
substrate-bound molecule (cyan). RMSD values of the overlays range from 0.235 – 0.833 Å, from at least 444 
aligned Cα atoms in each case. 
 
Figure 5.21 Crystal structure showing residues involved in the putative interacting network of the C-terminus of 
E372T a. Closed molecule of L-Kyn exposed E372T b. Open molecule of L-Kyn exposed E372T c. Closed 
molecule of L-Kyn free E372T d. Open molecule of L-Kyn free E372T. 2Fo-Fc maps are shown in blue (L-Kyn 
exposed molecules contoured at 0.26 eÅ-3, 1.0 σ, L-Kyn free molecules contoured at 0.25 eÅ-3, 1.0 σ). Distances 
between atoms are in Å and shown as red dashed lines. 
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As shown in Figure 5.20 and Figure 5.21 residue T372 is very similarly positioned in each molecule 
and plays no part in the putative interactive network. All distances depicted in Figure 5.21 are too large 
to indicate any meaningful interaction. This does not seem to affect the ability of the molecule to form 
a closed conformer. 
The interactivity of the proposed network has not been significant in any structure throughout this work. 
5.6. Surface calculations 
The analysis of void volume and surface area within the active site of dm2 yielded inconsistent results, 
as seen in chapter 3. The open molecule of dm2 was expected to have a larger void volume and a larger 
surface area in the active site and at the opening of the channel. In the substrate-bound model the volume 
was very similar in each molecule and the surface area larger in the open molecule. In the substrate-free 
model both the volume and the surface area were larger in the closed molecule. The data were not 
sufficient to draw any conclusions. Therefore, surface calculations for all the mutants presented so far 
in this thesis were performed to compare their active sites. Table 5.10 presents the surface area and void 

















Closed  376 413 Closed 383 449 
Open  374 431 Open 332 382 
R84K 
Closed  461 501 Closed 434 477 
Open  447 509 Open 433 476 
Y404F 
Closed  364 408 Closed 408 448 
Open  438 487 Open 407 465 
H320F 
Closed  335 393 Closed 370 424 
Open  365 431 Open 359 422 
R386K 
Closed  370 428 Closed 398 450 
Open  398 444 Open 379 438 
E372T 
Closed  398 444 Closed 385 445 
Open  370 428 Open 335 404 
Table 5.10 Void volume and surface area of the active site of both open and closed conformers of PfKMO 
variants. 
The data presented in Table 5.10 shows very little pattern or order. This matches most of the findings 
concerning the C-terminus of PfKMO. In some cases the active site of the closed molecule has 
significantly smaller volume and surface area, such as substrate-bound H320F. Other examples show 
the open molecule with the smaller values, such as substrate-free dm2. Some have very similar values 
for both volume and surface area; some differ in just one criterion. 
The difficulty in quantifying the surface area and volume of the active sites in these molecules may 
stem from the changes seen in the opening. As the C-terminus moves the extent of the opening differs. 
At times it is closed enough to act as a surface within the active site; other times the opening is large 
enough to become void volume and quickly becomes the surface of the protein. A very slight movement 
can result in large differences in the value of volume and surface area within the calculation. 
In previous work the hypothesis of substrate induced fit required the presence of a clearly defined 
channel opening to allow substrate access and exclude solvent. Throughout this thesis the opening, 
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much like the movement of the C-terminus, has been less binary than expected. It may therefore be 
thought of as more of a cleft than an established channel. This makes measuring the extent of opening 
and closing very difficult. Given the nature of the C-terminus movement, however, this may not be 
necessary. The study of the C-terminus throughout this thesis has shown no evidence toward substrate-
induced fit or the need for an interactive network between the C-terminus and the rest of the protein. 





Chapter 6: Conclusions 
The most important result of this work is the first high-resolution structure of substrate-bound KMO, 
determined at a resolution of 1.5 Å. The interactions between L-Kyn and the active site of dm2 can 
form a template for future inhibitor design. This has already impacted the design of potential inhibitors 
as noted in the soon to be published paper by Hutchinson et al.133, 154. 
Residues of the active site have also been successfully investigated including R84, Y404 and H320. 
The kinetic behaviour of these dm2 variants has been explained through structural findings. The 
importance of residues R84 and Y404 have been ratified and the introduction of the H320F substitution 
has afforded the structure of an active site homologous to that of hKMO. The similarity in binding 
observed in dm2 and H320F also affirms PfKMO as a suitable model for the study of hKMO and as a 
basis for inhibitor design. Despite exhaustive efforts the occupancy of substrate has been low in R84K 
and Y404F structures and required altered contouring of the 2Fo-Fc maps. Given the relatively high KM 
of L-Kyn followed by further alteration of the active site this, perhaps, is not surprising. Supporting 
factors for the case of low substrate occupancy include the fact that the substrate can be modeled with 
100% occupancy, the differences shown between the Fo-Fc maps of substrate-exposed and substrate-
free models and the supporting polder maps. 
The findings concerning the movement of the C-terminus are not straightforward. The most clear-cut 
conclusion surrounding the C-terminus movement is disproving the hypothesis that a ligand is required 
for dm2 to achieve a closed form. The work also disbands the proposed reliance upon an interactive 
network between the C-terminus and the rest of the protein in order to take up the closed conformation. 
Furthermore there is no evidence to imply the positioning of the C-terminus is caused by crystal contacts 
within the unit cell. 
The large body of data recorded throughout this work supports a proposal that the movement of the 
C-terminus is not controlled but is simply the result of high mobility and thermal motion. The 
positioning of the C-terminus follows no pattern throughout; it differs from crystal to crystal and has 
been effectively random. In many of the proteins studied certain datasets reduced the size of the ASU 
to include only one molecule. This was due to the molecules being similar enough to do so, thus 
implying the difference between C-termini was minimal. Other datasets of the same molecule have 
shown significant distinction between the two. 
This lack of clarity is echoed in the surface calculations for the active site and opening cleft. Given the 
proximity of the surface of the protein small differences in C-terminus positioning resulted in large 
differences in surface area and volume values. The calculations yielded unpredictable results that follow 
no clear pattern. These results, however, do not take away from the main conclusions concerning the 
C-terminus this thesis has put forward. 
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The movement of residues 240-290 is also haphazard enough to make any conclusions difficult. 
Evidence exists to support a connection between the motion of the C-terminus and these residues; given 
their movements are matched in a number of structures. This is, however, countered in other structures 
where movement of residues 240-290 is significantly less than expected. This movement may be the 
result of high mobility and thermal motion, and we are capturing snapshots of this motion. The motion 
may also be connected to movement of the C-terminus. The data presented does not allow for a strong 
conclusion either way. Given the positioning of these residues compared to the active site and the 
opening caused by the C-terminus movement the connection may not be particularly important anyway. 
The level of substrate occupancy also appears to be linked to the movement of the C-terminus. Multiple 
iterations of dm2 have been presented in this thesis; the molecules in the closed form often show 
evidence of substrate binding. The molecules in the open form show much less evidence of substrate 
binding. This can be explained as when dm2 is in the closed state the substrate is trapped within the 
molecule, when the molecule is open the L-Kyn can diffuse out of the active site, thus reducing 
occupancy.  This could be explained as conformational selection; wherein the fluid dynamism of KMO 
leads to the closed state and more effective binding of substrate. The findings in this thesis are in keeping 
with the findings of Changeux et al. in that the majority of data supports conformational selection over 
induced fit176. In summary the movement of the C-terminus may yet relate to substrate binding and that 
the relationship remains difficult to fully define. 
The work of industrial collaborators has also shown the presence of an open and closed molecule within 
the ASU. Using the same crystallising conditions both apo and inhibitor-bound structures showed the 
same movement between the two chains. One example is the competitive ligand GSK428. The IC50 of 
GSK428 is 60 nM implying a Ki two orders of magnitude lower than the KM of L-Kyn133, 154. This 
resulted in ligand binding in both molecules. Despite the low Ki the ligand still showed slightly different 
interactions within the active site. The more closed chain B shows more indirect water-bridged 
interactions, reminiscent of L-Kyn, than the open chain A. This matches with the findings presented in 





Figure 6.1 Crystal structure of dm2 bound with inhibitor GSK428. a. Binding site of chain A of the ASU shown in 
cyan b. Binding site of chain B of the ASU shown in blue. c. Structure of GSK428. Interactions are shown as 
dashed lines. The green sphere represents a chloride ion. Image adapted from the paper by Hutchinson et al. 
with permission from the authors133. (PDB: 5NAB) 
The failure to capture a substrate molecule within R386K and E372T can also be used to argue the link 
between the C-terminus and the binding of L-Kyn. The KM of R386K and E372T are so similar to dm2 
that one could expect the substrate to bind more easily, as seen in dm2 or H320F. The higher mobility 
of the C-terminus in R386K and E372T, implied by their higher B-factors, may mean L-Kyn is more 
likely to diffuse out of the active site. 
It is difficult to examine this theory with the data we currently have. In order to investigate the role of 
C-terminus movement in substrate binding it would be necessary to reduce its mobility. This could 
involve fixing the C-terminus of dm2 in an open or closed state, preferably both. Structural and kinetic 
study on this subject could improve our understanding of the role of the C-terminus. Introduction of 
cysteine substitutions could cause di-sulfide bonds to form between the C-terminus and the other 
domain of the protein, closing the channel to the active site. This may also have the effect of decreasing 
the solubility of the protein, due to unwanted di-sulfide bonds between molecules. This would lead to 
aggregation as seen in the wild type PfKMO. Given that dm2 already has two cysteine residues replaced, 
additional cysteines could prove problematic. 
The further work of industrial collaborators also led to a new kind of KMO inhibitor that may point 
towards a flavin movement within KMO and type A flavoprotein aromatic hydroxylase proteins in 
general. By adding an alkoxyl-linked pyridyl group the affinity of inhibitor GSK891, shown in Figure 
6.2, increased dramatically. It was established from the crystal structure the pyridine π-stacks with the 




Figure 6.2 Crystal structure of dm2 bound with inhibitor GSK891. a. Pyridyl group of GSK891 π-stacking with 
isoalloxazine of FAD. b. Overlay of crystal structures of dm2, exhibiting the tilt observed in FAD positioning 
(magenta is bound with inhibitor GSK891, cyan is bound with inhibitor GSK428). c. Structure of GSK891. 
Interactions are shown as dashed lines. Image adapted from the paper by Hutchinson et al. with permission from 
the authors133. 
Previous examples of KMO inhibition would stimulate peroxide generation since the 
flavin-C4a-hydroperoxide was still formed; turnover was then interrupted by the inhibitor blocking 
access of the substrate. Inhibitors like GSK891, however, do not stimulate peroxide production and in 
fact reduce basal levels. This implies a new form of inhibition, one where the flavin-C4a-hydroperoxide 
is not formed. It is hypothesised that the positioning of these pendant groups in inhibitors like GSK891 
blocks NADPH access to the FAD, so that FAD cannot be reduced, this is shown in Figure 6.3. This 
could lead to a new type of inhibition in KMO and potentially flavoproteins. Inhibitors that reduce 
peroxide formation are far more applicable in treating diseases, particularly neurological diseases like 
those associated with the KP. 
 
Figure 6.3 Crystal structure of dm2 bound with inhibitor GSK775. a. NADPH and L-Kyn (yellow) modelled into 
active site of the protein with GSK775 removed. b. Inhibitor GSK775 occupying the same space as modelled 
NADPH. c. Structure of GSK775. Image adapted from the paper by Hutchinson et al. with permission from the 
authors133. PDB 5NAE. 
Sadly the NADPH shown in Figure 6.3 is only modelled. This work would benefit significantly from a 
structure of KMO or a type A flavoprotein aromatic hydroxylase bound with NADPH showing an 
a b c 
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interaction between the flavin and NADPH. A confirmation of binding positioning of NADPH would 
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Chapter 7: Appendices 
7.1. Appendix 1 Crystallographic Data 
7.1.1. dm2 PfKMO 
 Substrate-bound Substrate-free 
Beamline I04-1 I02 
X-ray wavelength (Å) 0.9282 0.9795 
Space group P1 21 1 P1 21 1 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
69.93, 52.62, 137.99 
90.00, 104.07, 90.00 
 
69.74, 51.89, 136.29 
90.00, 103.69, 90.00 
Resolution (Å) 67.83-1.50 (1.58-1.50) 67.76-1.79 
CC1/2 0.998 (0.495) 0.999 (0.893) 
Rmerge 0.062 (0.614) 0.047 (0.300) 
Mean (I)/sd(I) 8.1 (1.7) 14.3 (4.1) 
Completeness (%) 99.7 (99.6) 99.6 (99.8) 
Multiplicity 3.1 (3.0) 3.4 (3.4) 
   
Rfactor 0.1797 (0.33) 0.1692 (0.21) 
Rfree 0.2142 (0.36) 0.2080 (0.26) 
No. reflections 155570 (22560) 89963 (13032) 
rmsd bond lengths (Å) 0.0228 0.0192 
rmsd bond angles (°) 2.1068 1.9531 
Ramachandran outliers (%) 0.81 1.40 
Mean B-factors (Å2) :   
Protein atoms 27.46 29.78 
Ligand atoms 18.20 16.83 
Waters 39.75 38.45 
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7.1.2. R84K PfKMO 
 Substrate-bound Substrate-free 
Beamline I04-1 I03 
X-ray wavelength (Å) 0.9282 0.9763 
Space group P1 21 1 P1 21 1 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
70.17, 52.38, 137.64 
90.00, 103.56, 90.00 
 
70.17, 53.16, 135.59 
90.00, 104.45, 90.00 
Resolution (Å) 68.22-1.70 (1.79-1.70) 67.95-1.80 (1.90-1.80) 
CC1/2 0.999 (0.486) 0.986 (0.852) 
Rmerge 0.046 (0.367) 0.113 (0.388) 
Mean (I)/sd(I) 10.9 (2.3) 4.6 (1.8) 
Completeness (%) 94.5 (90.0) 98.3 (98.1) 
Multiplicity 2.9 (2.3) 2.7 (2.6) 
   
Rfactor 0.1774 (0.33) 0.1879 (0.28) 
Rfree 0.2140 (0.33) 0.2283 (0.32) 
No. reflections 101305 (13991) 88433 (12831) 
rmsd bond lengths (Å) 0.0200 0.0186 
rmsd bond angles (°) 1.9937 1.9520 
Ramachandran outliers (%) 1.25 0.35 
Mean B-factors (Å2) :   
Protein atoms 30.39 31.84 
Ligand atoms 21.45 15.65 





7.1.3. Y404F PfKMO 
 Substrate-bound Substrate-free 
Beamline I04-1 I03 
X-ray wavelength (Å) 0.9282 0.9763 
Space group P1 21 1 P1 21 1 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
70.48, 52.99, 137.17 
90.00, 104.60, 90.00 
 
70.24, 52.30, 136.60 
90.00, 104.83, 90.00 
Resolution (Å) 68.20-1.80 (1.90-1.80) 67.90-1.65 (1.74-1.65) 
CC1/2 0.997 (0.662) 0.997 (0.800) 
Rmerge 0.069 (0.449) 0.070 (0.441) 
Mean (I)/sd(I) 8.4 (2.0) 8.7 (2.4) 
Completeness (%) 96.0 (96.0) 99.8 (99.8) 
Multiplicity 3.1 (2.5) 3.7 (3.5) 
   
Rfactor 0.1662 (0.30) 0.1748 (0.25) 
Rfree 0.2034 (0.33) 0.2099 (0.28) 
No. reflections 87357 (12690) 115511 (16759) 
rmsd bond lengths (Å) 0.0196 0.0201 
rmsd bond angles (°) 1.9149 2.0680 
Ramachandran outliers (%) 0.46 1.50 
Mean B-factors (Å2) :   
Protein atoms 31.79 33.15 
Ligand atoms 27.98 21.12 





7.1.4. H320F PfKMO 
 Substrate-bound Substrate-free 
Beamline I03 I03 
X-ray wavelength (Å) 0.9700 0.9700 
Space group P1 21 1 P1 21 1 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
69.09, 51.60, 136.28 
90.00, 103.96, 90.00 
 
69.44, 51.89, 135.95 
90.00, 103.94, 90.00 
Resolution (Å) 34.54-1.89 34.72-1.90 (2.01-1.90) 
CC1/2 0.999 (0.985) 0.995 (0.919) 
Rmerge 0.049 (0.132) 0.079 (0.303) 
Mean (I)/sd(I) 21.3 (9.4) 9.1 (3.4) 
Completeness (%) 99.8 (98.9) 99.7 (98.8) 
Multiplicity 6.0 (5.2) 4.3 (3.8) 
   
Rfactor 0.1550 (0.17) 0.1796 (0.23) 
Rfree 0.2005 (0.24) 0.2272 (0.30) 
No. reflections 74535 (10712) 74011 (10657) 
rmsd bond lengths (Å) 0.0188 0.0184 
rmsd bond angles (°) 1.9466 1.9007 
Ramachandran outliers (%) 0.24 0.70 
Mean B-factors (Å2) :   
Protein atoms 27.06 38.51 
Ligand atoms 23.71 24.33 





7.1.5. R386K PfKMO 
 Substrate-exposed Substrate-free 
Beamline I03 I03 
X-ray wavelength (Å) 0.9763 0.9763 
Space group P1 21 1 P1 21 1 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
66.12, 48.97, 129.36 
90.00, 103.69, 90.00 
 
70.16, 51.83, 136.72 
90.00 103.62 90.00 
Resolution (Å) 29.02-1.65 (1.69-1.65) 68.19-1.89 (2.00-1.89) 
CC1/2 0.998 (0.694) 0.996 (0.840) 
Rmerge 0.054 (0.482) 0.066 (0.323) 
Mean (I)/sd(I) 11.3 (2.1) 8.9 (2.9) 
Completeness (%) 99.5 (98.3) 99.4 (98.6) 
Multiplicity 3.3 2.9 (2.6) 
   
Rfactor 0.1720 (0.25) 0.1770 (0.25) 
Rfree 0.2095 (0.28) 0.2240 (0.30) 
No. reflections 96781 (7014) 76115 (10975) 
rmsd bond lengths (Å) 0.0396 0.0191 
rmsd bond angles (°) 2.6124 1.9490 
Ramachandran outliers (%) 0.47 0.91 
Mean B-factors (Å2) :   
Protein atoms 26.72 34.10 
Ligand atoms 19.01 21.98 





7.1.6. E372T PfKMO 
 Substrate-exposed Substrate-free 
Beamline I02 I02 
X-ray wavelength (Å) 0.9795 Å 0.9795 Å 
Space group P1 21 1 P1 21 1 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
69.81, 51.21, 136.41 
90.00, 104.13, 90.00 
 
69.50, 50.80, 136.03 
90.00, 104.46, 90.00 
Resolution (Å) 67.69-1.79 (1.89-1.79) 67.30-1.88 (1.99-1.88) 
CC1/2 0.998 (0.827) 0.994 (0.852) 
Rmerge 0.047 (0.437) 0.085 (0.481) 
Mean (I)/sd(I) 11.0 (2.6) 6.3 (2.0) 
Completeness (%) 99.5 (99.7) 99.1 (98.4) 
Multiplicity 3.1 (3.1) 3.4 (3.4) 
   
Rfactor 0.1856 (0.28) 0.1968 (0.31) 
Rfree 0.2310 (0.28) 0.2423 (0.32) 
No. reflections 88116 (12793) 73816 (10620) 
rmsd bond lengths (Å) 0.0179 0.0175 
rmsd bond angles (°) 1.8655 1.7968 
Ramachandran outliers (%) 1.16 0.90 
Mean B-factors (Å2) :   
Protein atoms 44.01 45.26 
Ligand atoms 27.51 28.18 
Waters 45.88 46.03 
 
 
